Parallax Health Sciences 10-Q 10 May 19 2019 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2019	May 14, 2019
Details
Registrant Name	PARALLAX HEALTH SCIENCES, INC.
Registrant CIK	0001388410
SEC Form	10-Q
Period End date	Mar. 31, 2019
Fiscal Year End	--12-31
Trading Symbol	prlx
Tax Identification Number (TIN)	464733512
Number of common stock shares outstanding		182,924,546
Filer Category	Non-accelerated Filer
Current with reporting	Yes
Small Business	true
Emerging Growth Company	false
Amendment Flag	false
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q1
Entity Incorporation, State Country Name	Nevada

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($)	Mar. 31, 2019	Dec. 31, 2018
Current assets
Cash and cash equivalents	$ 1,654	$ 262
Accounts receivable, net	25,180	0
Total current assets	26,834	262
Intangible assets, net	548,880	579,035
Goodwill	785,060	785,060
TOTAL ASSETS	1,360,774	1,364,357
Current liabilities
Accounts payable and accrued expenses	2,774,710	2,655,138
Debentures, convertible	572,535	755,627
Debentures, convertible, related party	472,471	428,132
Notes payable	20,000	0
Notes payable, convertible	506,913	296,000
Notes payable, convertible, related party	20,000	0
Related party payables	1,259,858	1,004,720
Total current liabilities	5,626,487	5,139,617
Long-term liabilities
License fees payable	433,000	430,000
Royalties payable	317,700	310,000
Debentures, convertible, net of unamortized discount	228,150	226,050
Notes payable, convertible	720,154	720,154
Notes payable, convertible, related party	491,100	491,100
Notes payable, bank	29,058	28,995
Total long-term liabilities	2,219,162	2,206,299
Total liabilities	7,845,649	7,345,916
Stockholders' deficit
Preferred stock	978	1,014
Common stock	170,259	158,113
Additional paid in capital-preferred	1,315,689	1,415,653
Additional paid in capital-common	10,974,574	9,715,921
Accumulated deficit	(18,946,375)	(17,272,260)
Total stockholders' deficit	(6,484,875)	(5,981,559)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	$ 1,360,774	$ 1,364,357

CONSOLIDATED BALANCE SHEETS - P

CONSOLIDATED BALANCE SHEETS - Parenthetical - $ / shares	Mar. 31, 2019	Dec. 31, 2018
Details
Preferred Stock, Par or Stated Value Per Share	$ 0.001	$ 0.001
Preferred Stock, Shares Authorized	10,000,000	10,000,000
Preferred Stock, Shares Outstanding	977,352	1,013,691
Common Stock, Par or Stated Value Per Share	$ 0.001	$ 0.001
Common Stock, Shares Authorized	500,000,000	250,000,000
Common Stock, Shares, Outstanding	170,259,136	158,113,141

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
CONSOLIDATED STATEMENTS OF OPERATIONS
Revenue	$ 50,990	$ 4,890
Cost of sales	5,111	5,538
Gross profit (loss)	45,879	(648)
General and administrative expenses	1,456,288	1,951,161
Operating loss	(1,410,409)	(1,951,809)
Other income (expenses)
Loss on settlements	(33,272)	0
Discount amortization	(130,420)	(1,335,000)
Interest expense	(100,014)	(323,149)
Total other income (expenses)	(263,706)	(1,658,149)
Net loss - continuing operations	(1,674,115)	(3,609,958)
Net loss - discontinued operations	0	(246,511)
Net loss	$ (1,674,115)	$ (3,856,469)
Net income (loss) per common share - basic
Continuing operations	$ (0.010)	$ (0.025)
Discontinued operations	0	(0.002)
Net income (loss) per common share - diluted
Continuing operations	(0.007)	(0.017)
Discontinued operations	$ 0	$ (0.002)
Weighted average common shares outstanding - basic	163,836,976	143,173,863
Weighted average common shares outstanding - diluted	233,000,282	202,447,083

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Cash flows from operating activities:
Net loss	$ (1,674,115)	$ (3,609,958)
Cash flows from discontinued operations:
Net cash used by operating activities	0	(80,230)
Net cash provided by financing activities	0	(3,636)
Net increase (decrease) in cash	1,392	(1,242)
Cash - beginning of period	262	2,604
Cash - end of period	1,654	1,362
NON-CASH ACTIVITIES
Discounts on long-term liabilities	130,420	1,335,000
Conversion of short-term related party notes payable to long-term non-related party notes payable	0	185,000
Conversion of accounts payable to notes payable	40,000	0
Conversion of convertible notes payable to common stock	290,000	0
Conversion of related party convertible note payable to non-related party convertible note payable	0	576,154
Conversion of related party payables to non-related party payables	0	165,353
Subscriptions receivable	0	(592)
Interest paid
Continuing operations	2,000	798
Discontinued operations	0	106
Income taxes paid	0	0
Adjustments to reconcile net loss to net cash used by operating activities:
Depreciation and amortization	(30,155)	(109,657)
Stock compensation/stock option amortization	(478,799)	(1,332,882)
Discount amortization	(130,420)	(1,335,000)
Allowance for bad debt	0	(236)
Changes in operating assets and liabilities:
(Increase) decrease in trade and other receivables	25,180	(2,859)
Increase in accounts payable and accrued expenses	(54,135)	(384,124)
Increase in royalties payable	(2,700)	0
Increase in related party payables	(275,138)	(261,824)
Net cash used by operating activities	(727,948)	(183,376)
Cash flows from financing activities:
Proceeds from convertible notes payable	(229,340)	(225,000)
Proceeds from issuance of common shares	(500,000)	(41,000)
Net cash provided by financing activities	729,340	266,000
Net cash provided by continuing operations	1,392	82,624
Net cash used by discontinued operations	$ 0	$ (83,866)

Overview and Nature of Business

Overview and Nature of Business	3 Months Ended
	Mar. 31, 2019
Notes
Overview and Nature of Business	NOTE 1. OVERVIEW AND NATURE OF BUSINESS These unaudited interim consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes for the year ended December 31, 2018. Notes to the unaudited interim consolidated financial statements that would substantially duplicate the disclosures contained in the audited consolidated financial statements have been omitted. Business Overview The Company’s principal focus is on personalized patient care through remote healthcare services, behavioral health systems, and Point-of-Care diagnostic testing. Parallax’s current family of companies that serve as the foundation for its cross-over business model of operations include: Parallax Diagnostics, Inc. Parallax Health Management, Inc. ® Parallax Behavioral Health, Inc. Parallax Care Optimized Outcomes REBOOT Behavioral modification Connected Health Fotodigm ® Remote patient monitoring, telehealth, and POC diagnostic testing Smart Data Intrinsic Code Actionable insights to behavior modification Operating Segments The Company’s operations include the following operating segments for financial statement presentation: Remote Patient Monitoring (RPM), Behavioral Health Services (BHS), and Diagnostics/Corporate. Remote Patient Monitoring The Company provides a distinctive technology platform that provides for the complete remote patient care delivery system: the patent-pending Fotodigm ® ® The RPM segment generates revenues through fees charged for the license and utilization of its proprietary system that provides software integrations of the Fotodigm ® Behavioral Health Services The BHS segment commenced with the acquisition of the REBOOT Diagnostics/Corporate The Diagnostics/Corporate Segment supports the costs and operating expenses related to the continued development and exploitation of the Company’s proprietary Target System POS diagnostic platform and processes. In addition, the Diagnostics/Corporate Segment provides management and administrative services to support the Company and consists of certain aspects of the Company’s executive management, corporate relations, legal, compliance, human resources, corporate information technology and finance departments. Going Concern The Company has incurred losses since inception resulting in an accumulated deficit of $18,946,375, and a working capital deficit of $5,599,653, and further losses are anticipated. The Company’s ability to continue as a going concern is dependent upon its ability to generate profitable operations in the future and/or to obtain the necessary financing to meet its obligations and repay its liabilities arising from normal business operations when they come due, which may not be available at commercially reasonable terms. There can be no assurance that the Company will be able to continue to raise funds, in which case the Company may be unable to meet its obligations and the Company may cease operations. These factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern. The Company will require additional financing in order to proceed with its plan of operations, including approximately $3,000,000 over the next 12 months to pay for its ongoing expenses. These cash requirements include working capital, general and administrative expenses, the development of the Company’s product line, and the pursuit of acquisitions. These cash requirements are in excess of the Company’s current cash and working capital resources. Accordingly, the Company will require additional financing in order to continue operations and to repay its liabilities. There is no assurance that the financing will be completed as planned or at all. If the Company is unable to secure adequate capital to continue the Company’s planned operations, the Company’s shareholders may lose some or all of their investment and the Company’s business may fail. The accompanying unaudited interim consolidated financial statements have been prepared in accordance with generally accepted accounting principles (“GAAP”). The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and that effect the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. The unaudited interim consolidated financial statements reflect all adjustments consisting of normal recurring adjustments, which, in the opinion of management, are necessary for a fair presentation of the results for the periods shown. The unaudited interim consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts of and classification of liabilities that might be necessary in the event the Company cannot continue as a going concern. NOTE: The following notes and any further reference made to “the Company”, "we", "us", "our" and "Parallax" shall mean Parallax Health Sciences, Inc., and its wholly-owned subsidiaries, Parallax Diagnostics, Inc., Parallax Health Management, Inc., and Parallax Behavioral Health, Inc. unless otherwise indicated.

Significant Accounting Policies

Significant Accounting Policies	3 Months Ended
	Mar. 31, 2019
Notes
Significant Accounting Policies	NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation This summary of significant accounting policies is presented to assist in understanding the Company’s financial statements. These accounting policies conform to accounting principles, generally accepted in the United States of America, and have been consistently applied in the preparation of the financial statements. The Company’s fiscal year-end is December 31. Principles of Consolidation The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated. Changes in the Company’s ownership interests in subsidiaries that do not result in the Company losing control over the subsidiaries are accounted for as equity transactions. When the Company loses control of a subsidiary, a gain or loss is recognized and is calculated as the difference between: the aggregate of the fair value of consideration received and the fair value of any retained interest at the date when control is lost; and the carrying amount of the net assets (liabilities) of the subsidiary and any noncontrolling interest. Upon deconsolidation of a subsidiary, any loans to the former subsidiary made by the Company are measured at fair value at the deconsolidation date. Any difference between the carrying amount of the loan to the subsidiary and its fair value is included as part of the gain or loss calculation upon deconsolidation. Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts in the consolidated financial statements and accompanying notes. Actual results could differ from those estimates. Fair Value Hierarchy The Company utilizes the three-level valuation hierarchy for the recognition and disclosure of fair value measurements. The categorization of assets and liabilities within this hierarchy is based upon the lowest level of input that is significant to the measurement of fair value. The three levels of the hierarchy consist of the following: Level 1: Inputs to the valuation methodology are unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date. Level 2: Inputs to the valuation methodology are quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active or inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the instrument. Level 3: Inputs to the valuation methodology are unobservable inputs based upon management’s best estimate of inputs market participants could use in pricing the asset or liability at the measurement date, including assumptions about risk. Cash and Cash Equivalents The Company considers all highly liquid instruments with maturity of nine months or less at the time of issuance to be cash equivalents. As of March 31, 2019, and December 31, 2018, the Company had no cash equivalents. Fair Value of Financial Instruments As of March 31, 2019, and December 31, 2018, respectively, the carrying values of Company’s Level 1 financial instruments including cash and cash equivalents, accounts receivable, accounts payable, and short-term debt approximate fair value. The fair value of Level 3 instruments is calculated as the net present value of expected cash flows based on externally provided or obtained inputs. Certain Level 3 instruments may also be based on sales prices of similar assets. The Company’s fair value calculations take into consideration the credit risk of both the Company and its counterparties as of the date of valuation. See Note 6 for additional information about long-term debt. There were no outstanding derivative financial instruments held by the Company as of March 31, 2019, and December 31, 2018. Accounts Receivable Accounts receivable are stated net of an allowance for doubtful accounts. The accounts receivable balance primarily includes amounts due from customers. Charges to bad debt are based on both historical write-offs and specifically identified receivables. The activity in the allowance for doubtful accounts receivable for the three months ended March 31, 2019, and the year ended December 31, 2018, respectively, is as follows: March 31, 2019 December 31, 2018 Beginning balance $ –– $ 4,000 Additions charged to bad debt expense –– 236 Write off of allowance for doubtful collections –– (4,236 ) Ending balance $ –– $ –– During the three months ended March 31, 2019, and the year ended December 31, 2018, the allowance for doubtful collections increased by $0 and $236, respectively. As of March 31, 2019, and December 31, 2018, no allowance for doubtful collections remained. Intangible Assets Product processes, patents and customer lists are amortized on a straight-line basis over their estimated useful lives between 4 and 20 years. Costs to extend and maintain patents and trademarks are charged directly to expense as incurred. See Note 4 for additional information about intangible assets. Goodwill and Other Indefinitely-Lived Assets Goodwill and other indefinitely-lived assets are not amortized, but are subject to impairment reviews annually, or more frequently if necessary. Impairment of Long-Lived Assets The Company evaluates long-lived assets for impairment whenever events or changes in circumstances indicate that their net book value may not be recoverable. When such factors and circumstances exist, the Company compares the projected undiscounted future cash flows associated with the related asset or group of assets over their estimated useful lives against their respective carrying amount. Impairment, if any, is based on the excess of the carrying amount over the fair value, based on market value when available, or discounted expected cash flows, of those assets and is recorded in the period in which the determination is made. The Company believes that future projected cash flows are sufficient for the recoverability of its long-lived assets, and no impairment exists. There can be no assurance, however, that market conditions will not change or demand for the Company’s products and products under development will continue. Either of these could result in future impairment losses. Convertible Debt The Company recognizes the advantageous value of conversion rights attached to convertible debt. Such rights give the debt holder the ability to convert debt into common stock at a price per share that is less than the trading price to the public on the date of the debt. The beneficial value is calculated as the intrinsic value (the market price of the stock at the commitment date in excess of the conversion rate) of the beneficial conversion feature of the debt, and is recorded as a discount to the related debt and an addition to additional paid in capital. The discount is amortized over the remaining outstanding period of related debt using the interest method. Net Income (Loss) Per Common Share Net loss per common share is computed by dividing net loss by the weighted average number of shares of common stock and dilutive common stock equivalents outstanding during the period. Dilutive common stock equivalents consist of shares issuable upon conversion of convertible debt, convertible preferred shares and the exercise of the Company’s stock options and warrants. Comprehensive Loss As of March 31, 2019, and December 31, 2018, the Company has no items that represent comprehensive loss and, therefore, has not included a schedule of comprehensive loss in the financial statements. Revenue Recognition Revenue is recognized when: (i) persuasive evidence of an arrangement exists, (ii) delivery has occurred or services have been rendered, (iii) the seller’s price to the buyer is fixed or determinable, and (iv) collectability is reasonably assured. Income Taxes Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. These assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which the temporary differences are expected to reverse. The Company may have net operating loss carryforwards available to reduce future taxable income. Future tax benefits for these net operating loss carryforwards are recognized to the extent that realization of these benefits is considered more likely than not. To the extent that the Company will not realize a future tax benefit, a valuation allowance is established. As of March 31, 2019, the Company has not yet filed its 2012 through 2017 annual corporate income tax returns. Due to the Company’s recurring losses, it is anticipated that no corporate income taxes are due for these periods. Stock-Based Compensation The Company records stock-based compensation using the fair value method. All transactions in which goods or services are the consideration received for the issuance of equity instruments are accounted for based on the fair value of the consideration received or the fair value of the equity instrument issued, whichever is more reliably measurable. Equity instruments issued to employees and the cost of the services received as consideration are measured and recognized based on the fair value of the equity instruments issued. Recently Adopted Accounting Standards The Company evaluates the pronouncements of various authoritative accounting organizations, primarily the Financial Accounting Standards Board (“FASB”), the US Securities and Exchange Commission (“SEC”), and the Emerging Issues Task Force (“EITF”), to determine the impact of new pronouncements on US GAAP and the impact on the Company. The Company has recently adopted the following new accounting standards: Adopted In June 2018, the FASB issued ASU No 2018-07 (“ASU 2018-07”), Compensation-Stock Compensation (Topic 718), Improvements to Nonemployee Share-Based Payment Accounting. ASU 2018-07 expands the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees. ASU 2018-07 will be effective for the Company for annual periods beginning after December 15, 2018, and interim periods. Early adoption is permitted. Not yet adopted In August 2018, the FASB issued ASU No. 2018-13 (“ASU 2018-13”), Fair Value Measurement (Topic 820), Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement. ASU 2018-13 modifies the disclosure requirements on fair value measurements in Topic 820, Fair Value Measurement, based on the concepts in the Concepts Statement, including the consideration of costs and benefits. ASU 2018-13 will be effective for the Company for annual periods beginning after December 15, 2019, and interim periods. Early adoption is permitted. The Company is currently evaluating the impact of the application of this accounting standard update on its financial statements and related disclosures. In August 2018, the FASB issued ASU No. 2018-15 (“ASU 2018-15”), Intangibles-Goodwill and Other Internal-Use Software (Subtopic 350-40). ASU 2018-15 was issued to help entities evaluate the accounting for fees paid by a customer in a cloud computing arrangement (hosting arrangement) by providing guidance for determining when the arrangement includes a software license. ASU 2018-15 will be effective for the Company for annual periods beginning after December 15, 2019, and interim periods. Early adoption is permitted. The Company is currently evaluating the impact of the application of this accounting standard update on its financial statements and related disclosures. Recently Issued Accounting Standards Updates: There were other various updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries. None of the updates are expected to a have a material impact on the Company's consolidated financial position, results of operations or cash flows.

Accounts Receivable, Net

Accounts Receivable, Net	3 Months Ended
	Mar. 31, 2019
Notes
Accounts Receivable, Net	NOTE 3. ACCOUNTS RECEIVABLE, NET Accounts receivable, net, consists of the following: March 31, 2019 December 31, 2018 Customer receivables $ 25,180 $ –– Less: allowance for doubtful accounts –– –– Accounts receivable, net $ 25,180 $ –– As of March 31, 2019, and December 31, 2018, respectively, the Company was owed $25,180 and $0 in accounts receivable due from customers. During the three months and the year ended March 31, 2019, and December 31, 2018, respectively, the allowance for doubtful collections increased by $0 and $236, respectively. As of March 31, 2019, and December 31, 2018, no allowance for doubtful collection remained.

Intangible Assets

Intangible Assets	3 Months Ended
	Mar. 31, 2019
Notes
Intangible Assets	NOTE 4. INTANGIBLE ASSETS The following are the components of finite-lived intangible assets: March 31, 2019 December 31, 2018 Products and processes $ 12,500 $ 12,500 Trademarks and patents / technology 150,700 150,700 Customer lists / relationships 30,000 30,000 Non-compete agreement 30,000 30,000 Marketing related 64,000 64,000 Software 510,300 510,300 Sub-total 797,500 797,500 Accumulated amortization (248,620 ) (218,465 ) Intangible assets, net $ 548,880 $ 579,035 Amortization expense from continuing operations for the three months ended March 31, 2019 and 2018, was $30,155 and $120,620, respectively.

Accounts Payable and Accrued Ex

Accounts Payable and Accrued Expenses	3 Months Ended
	Mar. 31, 2019
Notes
Accounts Payable and Accrued Expenses	NOTE 5. ACCOUNTS PAYABLE AND ACCRUED EXPENSES Accounts payable and accrued expenses consist of: March 31, 2019 December 31, 2018 Accounts payable-vendors $ 858,218 $ 830,590 Credit cards payable 42,552 42,552 Payroll taxes payable 79,362 78,608 Accrued interest 547,383 450,187 Accrued payroll and payroll taxes 482,047 402,053 Other liabilities 605,148 601,148 2,614,710 2,405,138 Reserve-legal fees 160,000 250,000 Total accounts payable and accrued expenses $ 2,774,710 $ 2,655,138 Payroll taxes payable includes $17,476 and $17,476 in penalties, and $4,957 and $4,202 in interest, related to unpaid payroll taxes as of March 31, 2019, and December 31, 2018, respectively. Other liabilities consists of certain payroll tax liabilities in the amount of $501,148 and $601,148 owed as of March 31, 2019, and December 31, 2018, respectively, by the bankrupt entity, RoxSan Pharmacy, Inc., that were not discharged under California bankruptcy laws. The Company has retained a tax resolution specialist to aid the Company in resolving the liability with the taxing agencies on behalf of RoxSan. In addition, other liabilities includes $104,000 and $0 in costs related to certain legal settlements as of March 31, 2019, and December 31, 2018, respectively. During the year ended December 31, 2018, accounts payable and accrued expenses was reduced by $341,606, resulting from the extinguishment of debt consisting of accounts payable-vendors in the amount of $284,714 and accrued interest in the amount of $56,892. In 2018, the Company established a reserve for future legal fees to be incurred in connection with pending legal actions (Note 16). During the three months and the year ended March 31, 2019 and December 31, 2018, respectively, the reserve for legal fees was reduced by $90,000 and $0 for expenses incurred during the period. As of March 31, 2019, and December 31, 2018, respectively, the reserve balance is $160,000 and $250,000.

Notes and Loans Payable

Notes and Loans Payable	3 Months Ended
	Mar. 31, 2019
Notes
Notes and Loans Payable	NOTE 6. NOTES AND LOANS PAYABLE Notes and loans payable consists of the following: March 31, 2019 December 31, 2018 Short-term Debentures, convertible $ 572,535 $ 755,627 Notes payable 20,000 –– Notes payable, convertible , net of unamortized discount 506,913 296,000 Total short-term 1,099,448 1,051,627 Long-term Debentures, convertible, net of unamortized discount 228,150 226,050 Note payable, convertible 720,154 720,154 Note payable-bank 29,058 28,995 Total long-term 977,362 975,199 Total notes and loans payable $ 2,076,810 $ 2,026,826 Non-related party convertible debt consist of the following: Holder Principal APR Accrued Interest Conversion Price Term/Due Convertible promissory notes: Short-term Lender Group A $ 120,000 12% to 20% $ 203,460 $0.10 05 /31 Lender Group B 230,913 12% –– $0.10 to $0.12 09 /30 /30 Investor Group A 156,000 10% 23,527 $0.10 09 /30 506,913 226,987 Long-term The Kasper Group, Ltd. 144,000 7% 73,073 $0.10 10 /31 Joseph M. Redmond 576,154 5% 126,653 $0.10 07 /31 720,154 199,726 1,227,067 426,713 Convertible debentures: Short-term 572,535 10% 22,131 $0.12 02 /28 Long-term 250,000 10% –– $0.12 11 /30 Unamortized discount (21,850 ) 10% –– 800,685 22,131 Total convertible debt $ 2,027,752 $ 448,844 As of March 31, 2019, and December 31, 2018, respectively, short-term non-related party debt in the amount of $1,099,448 and $1,051,627 consists of $572,155 and $755,627 in convertible debentures; $20,000 and $0 in notes payable; and $506,913 and $296,000 in convertible notes payable. During the three months and the year ended March 31, 2019, and December 31, 2018, respectively, principal in the amount of $0 and $50,000 was repaid in cash; principal in the amount of $20,000 and $620,000, along with interest in the amount of $2,000 and $55,613, was converted to common stock; and interest in the amount of $65,377 and $370,650 was expensed. As of March 31, 2019, and December 31, 2018, respectively, a total of $249,118 and $185,741 in accrued interest remains, and is included as an accrued expense on the accompanying consolidated balance sheet. As of March 31, 2019, and December 31, 2018, respectively, long-term non-related party debt in the amount of $977,362 and $975,199 consists of $250,000 and $250,000 in convertible debentures, less unamortized discount of $21,850 and $23,950; $720,154 and $720,154 in convertible notes payable; and $29,058 and $28,995 in notes payable to banks. During the three months and the year ended March 31, 2019, and December 31, 2018, respectively, $2,100 and $1,050 in discount amortization, and $10,139 and $40,956 in interest was expensed. As of March 31, 2019, and December 31, 2018, respectively, a total of $200,462 and $40,956 in accrued interest remains, and is included as an accrued expense on the accompanying consolidated balance sheet. The future maturities of notes payable are summarized as follows: Year 2019 2020 2021 Total Principal $720,154 $29,058 $250,000 $999,212 During the three months and the year ended March 31, 2019, and December 31, 2018, respectively, interest on non-related party notes and loans payable in the amount of $75,516 and $40,956 has been expensed. As of March 31, 2019, and December 31, 2018, respectively, a total of $449,580 and $376,127 in interest has been accrued and is included as part of accrued expenses on the accompanying consolidated balance sheets.

Related Party Transactions

Related Party Transactions	3 Months Ended
	Mar. 31, 2019
Notes
Related Party Transactions	NOTE 7. RELATED PARTY TRANSACTIONS Related party transactions consist of the following: March 31, 2019 December 31, 2018 Related party payables: Accrued compensation $ 950,325 $ 869,859 Cash advances 309,533 134,861 Total related party payables 1,259,858 1,004,720 Debentures, convertible 472,470 428,132 Notes payable, convertible, related party 511,100 491,100 Total related party transactions $ 2,243,428 $ 1,923,952 Related party convertible debt consist of the following: Note Holder Principal APR Accrued Interest Conversion Price Term/Due Convertible promissory notes: Huntington Chase, Beneficial Owner $ 491,100 7% $ 82,537 $0.10 12 /31 John Ogden, Director 20,000 10% –– $0.10 12 /31 $ 511,100 $ 82,537 Convertible debentures: AvantGarde, LLC, Beneficial Owner 393,989 12% 12,729 $0.10 02 /28 Hamburg Investment Co., Beneficial Owner 78,482 12% 2,536 $0.10 02 /28 472,470 15,265 Total convertible debt-related parties $ 983,570 $ 97,802 As of March 31, 2019, and December 31, 2018, respectively, related parties are due a total of $2,243,428 and $1,923,952, consisting of $950,325 and $869,859 in accrued compensation owed to officers; $309,533 and $134,861 in accrued benefits and cash advances from officers and beneficial owners to the Company for operating expenses; $472,470 and $428,132 in convertible debentures; and $511,100 and $491,100 in convertible promissory notes. During the three months and the year ended March 31, 2019, and December 31, 2018, respectively, interest on related party notes payable in the amount of $23,742 and $123,133 was expensed, of which -$0 and -$798 was paid to the note holders in cash; and -$0 and -$128,132 was converted to principal. As of March 31, 2019, and December 31, 2018, respectively, a total of $97,802 and $74,060 in accrued interest remains and is included as part of accrued expenses on the accompanying consolidated balance sheets.

Commitments And Contingencies

Commitments And Contingencies	3 Months Ended
	Mar. 31, 2019
Notes
Commitments And Contingencies	NOTE 8. COMMITMENTS AND CONTINGENCIES On August 13, 2015, the Company issued a secured promissory note in the amount of $20,500,000 (the “Promissory Note”) in connection with the acquisition of RoxSan Pharmacy, Inc. (“RoxSan”). The Promissory Note bore interest at a rate of 6% per annum, and matured August 13, 2018 ("Maturity"). As part of the deconsolidation of RoxSan resulting from its Chapter 7 petition filed on May 14, 2018 (Note 16), management reevaluated the characteristics of the Promissory Note. Included in the evaluation were the following considerations: 1) the related asset is no longer a part of the parent financial statements due to a loss of financial control; 2) the Company is currently in litigation as a result of material breaches by the note holder; 3) the Company has claims against the note holder for losses and damages directly related to the Promissory Note and its underlying assets; 4) there is a high likelihood that no obligation exists. After careful consideration, management has determined that the current characteristics of the liability are contingent in nature, and the debt $20,500,000 and related $2,278,281 in accrued interest was extinguished in 2018, resulting in a gain of $22,778,281. On August 31, 2016, as part of the Company’s acquisition of 100% of the issued and outstanding shares of Qolpom ® ® On April 26, 2017, as part of the Company’s acquisition of certain intellectual property (“Intellectual Property”) from ProEventa, Inc (“ProEventa”), the agreement provides for, among other things, ProEventa to receive a revenue sharing cash earn-out of up to $3,000,000 to be derived from certain net revenue generated by the Company; as well as Royalties of 3% of certain revenues generated from the Intellectual Property, ending at such time as the Company has paid ProEventa $25,000,000, as defined in the agreement. As of March 31, 2019, and December 31, 2018, respectively, the present value of future Revenue Share was $1,042,000 and $1,040,000; the present value of future Royalties was $693,000 and $690,000, and $2,700 and $0 in Royalties payable on earned revenues was accrued.

Convertible Preferred Stock

Convertible Preferred Stock	3 Months Ended
	Mar. 31, 2019
Notes
Convertible Preferred Stock	NOTE 9. CONVERTIBLE PREFERRED STOCK The total number of authorized shares of preferred stock that may be issued by the Company is 10,000,000 with a par value of $0.001 per share. On March 31, 2019, in connection with the settlement agreement with Mr. Dave Engert (Note 16), 36,339 shares of the Company’s Series A preferred stock held by Mr. Engert , with a book value of $100,000, were canceled and returned to treasury. As a result, preferred paid in capital was reduced by $99,964. As of March 31, 2019, and December 31, 2018, respectively, the Company had 977,352 and 1,013,691 shares of preferred stock issued and outstanding.

Common Stock

Common Stock	3 Months Ended
	Mar. 31, 2019
Notes
Common Stock	NOTE 10. COMMON STOCK On January 28, 2019, pursuant to a majority shareholder consent, the Company increased its authorized common stock from 250,000,000 shares to 500,000,000 shares, with a par value of $0.001 per share. During the three months ended March 31, 2019, 3,689,328 shares of the Company’s common stock were issued in connection with the conversion of non-related party debt in the amount of $292,000. As a result, $288,311 was recorded to paid in capital. During the three months ended March 31, 2019, 2,716,667 shares of the Company’s common stock were issued in connection with stock awards to non-related parties, valued at $325,000. As a result, $322,283 was recorded to paid in capital. During the three months ended March 31, 2019, 5,000,000 shares of the Company’s common stock were issued in connection with a Simple Agreement Future Equity (“SAFE”) offering for cash in the amount of $500,000. As a result, $495,000 was recorded to paid in capital. During the three months ended March 31, 2019, 740,000 shares of the Company’s common stock were issued in connection with debt and debt service in the amount of $74,000. As a result, $73,260 was recorded to paid in capital. During the three months and the year ended March 31, 2019, and December 31, 2018, respectively, a total of 12,145,995 and 21,358,611 shares of the Company’s common stock were issued. A total of $74,000 and $434,000 in deferred stock compensation was recorded, and $124,357 and $1,095,193 was expensed. As of December 31, 2018 and 2017, respectively, there remains $1,098,452 and $1,148,809 in deferred stock compensation to be expensed over the next nineteen (19) months. As of March 31, 2019 and December 31, 2018, respectively, the Company had 170,259,136 and 158,113,141 common shares issued and outstanding.

Warrants And Options

Warrants And Options	3 Months Ended
	Mar. 31, 2019
Notes
Warrants And Options	NOTE 11. WARRANTS AND OPTIONS As of March 31, 2019, and December 31, 2018, respectively, the Company had 20,968,750 and 19,668,750 warrants, and 19,060,000 and 18,060,000 options, issued and outstanding. During the three months and the year ended March 31, 2019 and December 31, 2018, respectively, 1,600,000 and 12,513,750 warrants were granted, and 300,000 and 100,000 expired. The warrants carry an exercise price of between $0.001 to $0.600 per share, and expire between 2019 to 2023. Warrants Outstanding Number of Remaining Exercise Price Weighted Common Contractual Life Times Number Average Exercise Price Shares (in years) Of Shares Exercise Price $0.001 300,000 4.25 $ 300 $0.17 $0.01 75,000 1.75 750 $0.19 $0.10 62,500 4.00 6,250 $0.27 $0.10 3,000,000 2.25 300,000 $0.19 $0.10 4,688,750 2.00 468,875 $0.21 $0.10 250,000 1.50 25,000 $0.29 $0.15 300,000 5.00 45,000 $0.17 $0.15 600,000 4.75 90,000 $0.19 $0.15 1,000,000 1.75 150,000 $0.26 $0.17 62,500 4.00 10,625 $0.27 $0.18 62,500 4.00 11,250 $0.27 $0.20 1,300,000 5.00 260,000 $0.18 $0.21 62,500 4.00 13,125 $0.27 $0.21 100,000 1.50 21,000 $0.31 $0.25 3,375,000 2.50 843,750 $0.18 $0.25 475,000 1.75 118,750 $0.25 $0.25 3,255,000 1.50 813,750 $0.29 $0.25 1,500,000 1.25 375,000 $0.34 $0.35 250,000 1.50 87,500 $0.29 $0.60 250,000 1.50 150,000 $0.31 20,968,750 3,790,925 $0.18 Warrant Activity Weighted Number of Average Shares Exercise Price Outstanding at December 31, 2018 19,668,750 $0.18 Issued 1,600,000 $0.18 Exercised –– –– Expired / Forfeited (300,000 ) $0.18 Outstanding at March 31, 2019 20,968,750 $0.18 During the three months and the year ended March 31, 2019, and December 31, 2018, respectively, 1,000,000 and 6,000,000 stock options were granted, which vest periodically over a two (2) year period, are exercisable for a period of between 3 to 5 years at an exercise price of between $0.05 to $0.50 per share, and were valued at $96,100 and $833,700 using the Black-Scholes method. The assumptions used in valuing the options were: expected term between 3.00 to 3.75 years; expected volatility between 1.82 to 2.29; risk free interest rate of between 2.25% to 2.78%; and a dividend yield of 0%. Options Outstanding Number of Remaining Exercise Price Weighted Common Contractual Life Times Number Average Exercise Price Shares (in years) Of Shares Exercise Price $0.05 90,000 3.25 $ 4,500 $0.14 $0.05 1,140,000 3.00 57,000 $0.09 $0.05 100,000 2.50 5,000 $0.08 $0.05 60,000 1.75 3,000 $0.06 $0.05 170,000 1.50 8,500 $0.12 $0.10 500,000 1.50 50,000 $0.14 $0.10 250,000 0.50 25,000 $0.06 $0.15 1,000,000 1.50 150,000 $0.14 $0.25 1,000,000 4.75 250,000 $0.23 $0.25 5,000,000 4.00 1,250,000 $0.16 $0.25 7,000,000 3.25 1,750,000 $0.16 $0.25 1,000,000 1.50 250,000 $0.15 $0.25 1,000,000 1.00 250,000 $0.10 $0.25 250,000 0.50 62,500 $0.06 $0.35 250,000 0.50 87,500 $0.07 $0.60 250,000 0.50 150,000 $0.08 19,060,000 $ 4,353,000 $0.23 Options Activity Weighted Number of Average Shares Exercise Price Outstanding at December 31, 2018 18,060,000 $0.23 Issued 1,000,000 $0.23 Exercised –– –– Expired / Forfeited –– –– Outstanding at March 31, 2019 19,060,000 $0.23 During the three months and the year ended March 31, 2019, and December 31, 2018, respectively, 1,000,000 and 6,000,000 options were issued, 0 and 1,973,189 options were exercised, 0 and 1,000,000 options expired, and 0 and 5,641,811 options were forfeited. A total of $96,100 and $649,327 in deferred stock option compensation was recorded, net of forfeitures, and $29,442 and $572,870 was expensed during the three months and the year ended March 31, 2019, and December 31, 2018, respectively. There remains $1,462,124 and $1,395,466 in deferred compensation as of March 31, 2019, and December 31, 2018, respectively, to be expensed over the next 21 months.

Leases

Leases	3 Months Ended
	Mar. 31, 2019
Notes
Leases	NOTE 12. LEASES The Company sub-leases office space for its headquarters in Santa Monica, California, for $5,600 per month, on a month-to-month basis. Rent expense for the three months ended March 31, 2019 and 2018, was $17,360 and $19,397, respectively.

Income Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2019
Notes
Income Taxes	NOTE 13. INCOME TAXES A reconciliation of the expected statutory federal and state taxes and the total income tax expense (benefit) at March 31, 2019, and December 31, 2018, was as follows: March 31 2019 December 31, 2018 Income (loss) before taxes $ (1,674,115 ) $ 17,113,718 Statutory rate (Fed & State(s)) 30% 30% Computed expected tax payable (recovery) (422,200 ) 5,230,900 Effect of release of net operating loss carryforwards (927,100 ) (2,738,100 ) Tax effect of non-deductible expenses: Gain on extinguishment of debt-principal –– (6,230,700 ) Stock compensation/amortization of stock options 142,900 1,026,600 Discount amortization 38,900 837,300 Other 800 1,500 Total tax effect of non-deductible expenses 182,600 (4,365,300 ) Change in valuation allowance 1,166,700 (1,872,500 ) Income tax expense $ –– $ –– Reported income taxes: Federal $ –– $ –– State –– –– Total $ –– $ –– The significant components of deferred income tax assets and liabilities at March 31, 2019, and December 31, 2018, are as follows: March 31, 2019 December 31, 2018 Net operating loss carried forward $ 1,137,500 $ –– Bad debt allowance –– –– Officers’ accrued compensation 265,900 243,400 Accrued related party interest 27,400 20,700 Valuation allowance (1,430,800 ) (264,100 ) Net deferred income tax asset $ –– $ –– During the year ended December 31, 2018, the company realized extinguishment of debt principal in the amount of $20,880,688. Per Internal Revenue Code (“IRC”) Section 108(a) (1) (A) the extinguishment of debt principal is excluded from taxable income for the Company. However, any available tax attributes must be released up and to the amount of the extinguishment. Therefore, net operating loss carryforwards were released for the amount of income excluded from taxable income. The remaining net operating losses available to use toward future taxable income are as follows: Tax Year Net Operating Loss Expires 2016 442,900 2036 2017 2,115,400 2037 2018 548,900 No Expiration 2019 to date 957,900 No Expiration Total $ 4,065,100 As at March 31, 2019, the Company had approximately $4,065,100 of federal net operating losses, of which $1,506,800 have no expiration date. The Company is open to examinations for the tax year 2011 through the current tax year.

Discontinued Operations

Discontinued Operations	3 Months Ended
	Mar. 31, 2019
Notes
Discontinued Operations	NOTE 14. DISCONTINUED OPERATIONS In December 2017, the Company discontinued all operations related to the Retail Pharmacy Segment (RPS) involving the Company’s wholly-owned subsidiary, RoxSan Pharmacy, Inc. (“RoxSan”). On May 14, 2018, pursuant to a unanimous resolution of the Boards of Directors of RoxSan and Parallax Health Sciences, Inc., RoxSan filed a Chapter 7 petition in the United States Bankruptcy Court for the Central District of California. Mr. Timothy Yoo was appointed trustee on May 15, 2018. In connection with the filing, RoxSan sought to discharge approximately $5 million of liabilities owed to various parties, and intercompany loans in excess of $1 million owed to the Company. The Chapter 7 bankruptcy proceeding by was fully discharged and the case was closed on March 13, 2019. Due to, among other things, the reduction in RoxSan’s cash flows during 2016 and 2017, RoxSan became delinquent in its payroll tax depository obligations, resulting in a liability owed to federal and state taxing agencies in the aggregate of $1,148,811, which includes $601,148 in taxes withheld from employees (“Trust Fund Taxes”), employer taxes of $183,172, and penalties and interest of $364,491 through December 31, 2018. The liability was included as part of the Chapter 7 bankruptcy petition, and certain portions of the liability may be discharged. However, in accordance with California bankruptcy laws, federal and state Trust Fund Taxes are not dischargeable. The Company has retained a tax resolution specialist and is in communications with the taxing agencies in order to resolve RoxSan’s liability (Note 5). As a result of the loss of financial control of RoxSan, the Company derecognized the subsidiary effective May 14, 2018. The derecognition resulted in a gain of $4,478,268. The Company also extinguished $22,778,281 in debt and accrued interest related to the acquisition of RoxSan. The results of the discontinued operations of RoxSan Pharmacy, Inc. for the three months ending Mach 31, 2018, are summarized as follows: March 31, 2018 Revenue $ –– Cost of sales –– Gross profit –– General and administrative expenses 224,919 Operating loss (224,919 ) Interest expense (21,592 ) Net loss from discontinued operations $ (246,511 )

Segment Reporting

Segment Reporting	3 Months Ended
	Mar. 31, 2019
Notes
Segment Reporting	NOTE 15. SEGMENT REPORTING The Company has the following business segments: Remote Care Services (RCS), Behavioral Health Services (BHS), and Diagnostics/Corporate (DCS). See Note 1 and 2 for a description of each segment and related significant accounting policies. The following table is a reconciliation of the Company’s business segments to the consolidated financial statements: . Remote Care Segment Behavioral Health Segment Diagnostics/ Corporate Segment Discontinued Operations Consolidated Totals March 31, 2019 Revenue $ 540 $ 50,450 $ –– –– $ 50,990 Gross profit (loss) (4,571 ) 50,450 –– –– 45,879 Operating loss (86,483 ) (271 ) (1,323,655 ) –– (1,410,409 ) Depreciation and amortization 2,299 27,440 416 –– 30,155 Interest expense 755 –– 99,259 –– 100,014 Loss on settlements –– –– (33,272 ) –– (33,272 ) Discount amortization 8,000 –– 122,420 –– 130,420 Total assets 911,240 437,127 12,407 –– 1,360,774 Goodwill 785,060 –– –– –– 785,060 Additions to property and equipment –– –– –– –– –– March 31, 2018 Revenue 4,440 450 –– –– 4,890 Gross profit (loss) (1,098 ) 450 –– –– (648 ) Operating loss (72,258 ) (126,387 ) (1,753,165 ) –– (1,951,810 ) Depreciation and amortization 2,466 106,775 416 –– 109,657 Interest expense 708 –– 322,442 –– 323,150 Discount amortization 10,000 50,000 1,275,000 –– 1,335,000 Discontinued operations –– –– –– (246,511 ) (246,511 ) Total assets 931,060 2,030,841 13,133 242,454 [1] 3,217,488 Goodwill 785,060 –– –– –– 785,060 Additions to property and equipment –– –– –– –– –– [1] Assets held for sale .

Legal Matters

Legal Matters	3 Months Ended
	Mar. 31, 2019
Notes
Legal Matters	NOTE 16. LEGAL MATTERS The Company knows of no material developments to its legal matters other than those disclosed below: Dispute with Former Owner of RoxSan Action No. SC125702: In the Matter, action No. SC125702, in the Superior Court of the State of California, County of Los Angeles, West District, the former owner of RoxSan Pharmacy, Inc., Shahla Melamed (“Melamed”), alleges that the Company is in default under the terms of the Purchase Agreement and Secured Note, and the Company’s termination of Melamed’s employment agreement. The Company firmly believes that it had adequate grounds to justify the termination of the employment, that it acted within its rights, and shall prevail in these proceedings. A trial date, previously set for December 2018, is currently set for January 2020. Action No. SC 124898: The Company initiated legal action against Melamed and filed a complaint, action number SC 124898, in the Superior Court of the State of California, County of Los Angeles, West District, Parallax Health Sciences, et al. v. Shahla Melamed, et al. The Complaint in that action alleges that Melamed has breached several obligations under the Purchase Agreement, and the Company is seeking to reduce the Secured Note due to undisclosed material changes in the business. A trial date, previously set for December 2018, is currently set for January 2020. Disputes with Former Executives Action No. CV2017-052804 On March 9, 2017, Dave Engert former Executive Chairman and director of the Company filed a lawsuit in Arizona and then on or about May 5, 2017, Mr. Engert, changed the venue and filed suit against the Company and RoxSan Pharmacy, Inc. in the United States District Court, Central District of California for an amount exceeding $75,000. On October 23, 2017, the Company filed an answer and counterclaims against Mr. Engert for an amount exceeding $100,000. The counterclaims include possible fraud and negligence committed by Mr. Engert and Mr. J. Michael Redmond, former successor Chairman of Mr. Engert, director, President and Chief Executive Officer of the Company and former President, Chief Executive Officer, Chairman and director of RoxSan Pharmacy, Inc. On October 8, 2018, a settlement was reached between Mr. Engert and the Company (the “Settlement”). The Settlement includes, among other things, a cash payment to Mr. Engert in the amount of $139,000, and the cancellation of all of Mr. Engert’s equity holdings in the Company. The Settlement resulted in a net loss to the Company of $33,272. On April 10, 2019, a stipulation for dismissal was filed, and the matter has been fully resolved.

Subsequent Events

Subsequent Events	3 Months Ended
	Mar. 31, 2019
Notes
Subsequent Events	NOTE 17. SUBSEQUENT EVENTS The Company has evaluated the events and transactions for recognition or disclosure subsequent to March 31, 2019, through the date of the issuance of the financial statements, and has determined that there have been no events that would require disclosure, except for the following: In April 2019, the Company issued 12% convertible promissory notes in the aggregate principal sum of $214,000. The notes matures by April 2, 2020, and contain repayment provisions for the holders of the notes to convert the principal sum and any accrued interest into shares of the Company’s common stock at a conversion rate of the lesser of (i) $0.12 per share, or (ii) 65% of the average lowest trading prices during the trading days immediately preceding the conversion date. In addition, the Company issued warrants to purchase 300,000 shares of the Company’s common stock at an exercise price of $0.15 per share for a period of five (5) years. In April 2019, in connection with a certain convertible debenture, the holder elected to convert $105,000 into 2,340,410 shares of the Company’s restricted common stock. As a result, $102,660 was recorded to paid in capital. In April 2019, the Company issued 825,000 shares of its restricted common stock for various services valued at $80,500. As a result, $79,675 was recorded to paid in capital. In April 2019, the Company entered into an employment agreement with Mr. David Appell to serve as the Company’s Chief Operating Officer. The agreement commences May 15, 2019, is for an initial term of two (2) years, and provides a base compensation of $250,000 year one, and $275,000 in year two, as well as various performance bonuses, and customary employee benefits. In addition, the agreement includes a grant to purchase 3,000,000 restricted common shares at $0.001 per share, of which 25% vest immediately, and the remainder vest when certain earnings goals are met, as well as options granted to purchase 3,000,000 shares of the Company's Common Stock at an exercise price of $0.25 per share. The options are for a period of five (5) years, and vest annually over the term of the agreement, with an initial vesting of 25%. In addition, the Company entered into an employment agreement with Ms. Amanda L. Perry to serve as the Company’s Chief Legal Officer. The agreement commences May 15, 2019, is for an initial term of two (2) years, and provides a base compensation of $130,000 year one, and $140,000 in year two, as well as various performance bonuses, and customary employee benefits. In addition, the agreement includes a grant to purchase 500,000 restricted common shares at $0.001 per share, of which 25% vest immediately, and the remainder vest when certain earnings goals are met, as well as options granted to purchase 500,000 shares of the Company's Common Stock at an exercise price of $0.25 per share. The options are for a period of five (5) years, and vest annually over the term of the agreement, with an initial vesting of 25%. On May 1, 2019, the Company entered into a sub-lease for office space located at 28 West 36th Street, 8th Floor, New York, NY 10018. The lease is for a term of thirteen (13) months, with a monthly rent payment of $8,900. In May 2019, the Company amended the private placement equity offering (the “Offering”) previously established in March 2019. The revised Offering is for the purchase of the 50,000,000 shares, or a maximum of $6,000,000, in Common Stock, plus equal Warrants at an exercise price of $0.25 per share for a term of three (3) years (the Common Stock and the Warrants together, the “Units”). The Offering provides for, among other thing, the purchase of the Units at a price of $0.125 per share, with a minimum total Offering of $1,000,000, and a minimum investment of 200,000 shares, or $25,000. Prior to the Offering, the Company is selling $1,000,000 in Units through a Simple Agreement Future Equity (“SAFE”) offering. The SAFE Units are sold at a 20% discount of the offering Unit price of $0.125, and are not a part of, nor reduce, the $1,000,000 minimum. The initial closing will occur on or before June 15, 2019, unless extended by the Company in its discretion. The Company may sell Units in one or more closings. In connection with the SAFE offering, the Company issued 2,500,000 shares of its restricted common stock at $0.10 per share, for cash in the amount of $250,000. As a result, $247,500 was recorded to paid in capital. The Company retained Maxim Group, LLC (“Maxim”) to serve as its placement agent for the Offering. The Company has agreed to pay the placement agent a placement fee equal to 7% of the aggregate gross proceeds raised in the Offering and warrants exercisable for a term of five years to purchase 7% of the number of shares of common stock included in the Units sold in the Offering at an exercise price of $0.125 per share. In connection with the Company’s agreement with Maxim, the Company issued Maxim 1,000,000 shares of its restricted common stock, valued at $71,000. As a result, $70,000 was recorded to paid in capital. On May 6, 2019, in connection with an equity funding, the Company issued 6,000,000 shares of its restricted common stock for cash in the amount of $500,000. As a result, $494,000 was recorded to paid in capital

Significant Accounting Polici_2

Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2019
Policies
Basis of Presentation	Basis of Presentation This summary of significant accounting policies is presented to assist in understanding the Company’s financial statements. These accounting policies conform to accounting principles, generally accepted in the United States of America, and have been consistently applied in the preparation of the financial statements. The Company’s fiscal year-end is December 31.
Principles of Consolidation	Principles of Consolidation The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated. Changes in the Company’s ownership interests in subsidiaries that do not result in the Company losing control over the subsidiaries are accounted for as equity transactions. When the Company loses control of a subsidiary, a gain or loss is recognized and is calculated as the difference between: the aggregate of the fair value of consideration received and the fair value of any retained interest at the date when control is lost; and the carrying amount of the net assets (liabilities) of the subsidiary and any noncontrolling interest. Upon deconsolidation of a subsidiary, any loans to the former subsidiary made by the Company are measured at fair value at the deconsolidation date. Any difference between the carrying amount of the loan to the subsidiary and its fair value is included as part of the gain or loss calculation upon deconsolidation.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts in the consolidated financial statements and accompanying notes. Actual results could differ from those estimates.
Fair Value Hierarchy	Fair Value Hierarchy The Company utilizes the three-level valuation hierarchy for the recognition and disclosure of fair value measurements. The categorization of assets and liabilities within this hierarchy is based upon the lowest level of input that is significant to the measurement of fair value. The three levels of the hierarchy consist of the following: Level 1: Inputs to the valuation methodology are unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date. Level 2: Inputs to the valuation methodology are quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active or inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the instrument. Level 3: Inputs to the valuation methodology are unobservable inputs based upon management’s best estimate of inputs market participants could use in pricing the asset or liability at the measurement date, including assumptions about risk.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers all highly liquid instruments with maturity of nine months or less at the time of issuance to be cash equivalents. As of March 31, 2019, and December 31, 2018, the Company had no cash equivalents.
Fair Value of Financial Instruments	Fair Value of Financial Instruments As of March 31, 2019, and December 31, 2018, respectively, the carrying values of Company’s Level 1 financial instruments including cash and cash equivalents, accounts receivable, accounts payable, and short-term debt approximate fair value. The fair value of Level 3 instruments is calculated as the net present value of expected cash flows based on externally provided or obtained inputs. Certain Level 3 instruments may also be based on sales prices of similar assets. The Company’s fair value calculations take into consideration the credit risk of both the Company and its counterparties as of the date of valuation. See Note 6 for additional information about long-term debt. There were no outstanding derivative financial instruments held by the Company as of March 31, 2019, and December 31, 2018.
Accounts Receivable	Accounts Receivable Accounts receivable are stated net of an allowance for doubtful accounts. The accounts receivable balance primarily includes amounts due from customers. Charges to bad debt are based on both historical write-offs and specifically identified receivables. The activity in the allowance for doubtful accounts receivable for the three months ended March 31, 2019, and the year ended December 31, 2018, respectively, is as follows: March 31, 2019 December 31, 2018 Beginning balance $ –– $ 4,000 Additions charged to bad debt expense –– 236 Write off of allowance for doubtful collections –– (4,236 ) Ending balance $ –– $ –– During the three months ended March 31, 2019, and the year ended December 31, 2018, the allowance for doubtful collections increased by $0 and $236, respectively. As of March 31, 2019, and December 31, 2018, no allowance for doubtful collections remained.
Intangible Assets	Intangible Assets Product processes, patents and customer lists are amortized on a straight-line basis over their estimated useful lives between 4 and 20 years. Costs to extend and maintain patents and trademarks are charged directly to expense as incurred. See Note 4 for additional information about intangible assets.
Goodwill and Intangible Assets	Goodwill and Other Indefinitely-Lived Assets Goodwill and other indefinitely-lived assets are not amortized, but are subject to impairment reviews annually, or more frequently if necessary.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets The Company evaluates long-lived assets for impairment whenever events or changes in circumstances indicate that their net book value may not be recoverable. When such factors and circumstances exist, the Company compares the projected undiscounted future cash flows associated with the related asset or group of assets over their estimated useful lives against their respective carrying amount. Impairment, if any, is based on the excess of the carrying amount over the fair value, based on market value when available, or discounted expected cash flows, of those assets and is recorded in the period in which the determination is made. The Company believes that future projected cash flows are sufficient for the recoverability of its long-lived assets, and no impairment exists. There can be no assurance, however, that market conditions will not change or demand for the Company’s products and products under development will continue. Either of these could result in future impairment losses.
Convertible Debt	Convertible Debt The Company recognizes the advantageous value of conversion rights attached to convertible debt. Such rights give the debt holder the ability to convert debt into common stock at a price per share that is less than the trading price to the public on the date of the debt. The beneficial value is calculated as the intrinsic value (the market price of the stock at the commitment date in excess of the conversion rate) of the beneficial conversion feature of the debt, and is recorded as a discount to the related debt and an addition to additional paid in capital. The discount is amortized over the remaining outstanding period of related debt using the interest method.
Net Income (loss) Per Common Share	Net Income (Loss) Per Common Share Net loss per common share is computed by dividing net loss by the weighted average number of shares of common stock and dilutive common stock equivalents outstanding during the period. Dilutive common stock equivalents consist of shares issuable upon conversion of convertible debt, convertible preferred shares and the exercise of the Company’s stock options and warrants.
Comprehensive Loss	Comprehensive Loss As of March 31, 2019, and December 31, 2018, the Company has no items that represent comprehensive loss and, therefore, has not included a schedule of comprehensive loss in the financial statements.
Revenue Recognition	Revenue Recognition Revenue is recognized when: (i) persuasive evidence of an arrangement exists, (ii) delivery has occurred or services have been rendered, (iii) the seller’s price to the buyer is fixed or determinable, and (iv) collectability is reasonably assured.
Income Taxes	Income Taxes Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. These assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which the temporary differences are expected to reverse. The Company may have net operating loss carryforwards available to reduce future taxable income. Future tax benefits for these net operating loss carryforwards are recognized to the extent that realization of these benefits is considered more likely than not. To the extent that the Company will not realize a future tax benefit, a valuation allowance is established. As of March 31, 2019, the Company has not yet filed its 2012 through 2017 annual corporate income tax returns. Due to the Company’s recurring losses, it is anticipated that no corporate income taxes are due for these periods.
Stock-based Compensation	Stock-Based Compensation The Company records stock-based compensation using the fair value method. All transactions in which goods or services are the consideration received for the issuance of equity instruments are accounted for based on the fair value of the consideration received or the fair value of the equity instrument issued, whichever is more reliably measurable. Equity instruments issued to employees and the cost of the services received as consideration are measured and recognized based on the fair value of the equity instruments issued.
Recently Adopted Accounting Standards	Recently Adopted Accounting Standards The Company evaluates the pronouncements of various authoritative accounting organizations, primarily the Financial Accounting Standards Board (“FASB”), the US Securities and Exchange Commission (“SEC”), and the Emerging Issues Task Force (“EITF”), to determine the impact of new pronouncements on US GAAP and the impact on the Company. The Company has recently adopted the following new accounting standards: Adopted In June 2018, the FASB issued ASU No 2018-07 (“ASU 2018-07”), Compensation-Stock Compensation (Topic 718), Improvements to Nonemployee Share-Based Payment Accounting. ASU 2018-07 expands the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees. ASU 2018-07 will be effective for the Company for annual periods beginning after December 15, 2018, and interim periods. Early adoption is permitted. Not yet adopted In August 2018, the FASB issued ASU No. 2018-13 (“ASU 2018-13”), Fair Value Measurement (Topic 820), Disclosure Framework-Changes to the Disclosure Requirements for Fair Value Measurement. ASU 2018-13 modifies the disclosure requirements on fair value measurements in Topic 820, Fair Value Measurement, based on the concepts in the Concepts Statement, including the consideration of costs and benefits. ASU 2018-13 will be effective for the Company for annual periods beginning after December 15, 2019, and interim periods. Early adoption is permitted. The Company is currently evaluating the impact of the application of this accounting standard update on its financial statements and related disclosures. In August 2018, the FASB issued ASU No. 2018-15 (“ASU 2018-15”), Intangibles-Goodwill and Other Internal-Use Software (Subtopic 350-40). ASU 2018-15 was issued to help entities evaluate the accounting for fees paid by a customer in a cloud computing arrangement (hosting arrangement) by providing guidance for determining when the arrangement includes a software license. ASU 2018-15 will be effective for the Company for annual periods beginning after December 15, 2019, and interim periods. Early adoption is permitted. The Company is currently evaluating the impact of the application of this accounting standard update on its financial statements and related disclosures. Recently Issued Accounting Standards Updates: There were other various updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries. None of the updates are expected to a have a material impact on the Company's consolidated financial position, results of operations or cash flows.

Significant Accounting Polici_3

Significant Accounting Policies: Accounts Receivable: Allowance for Doubtful Accounts (Tables)	3 Months Ended
	Mar. 31, 2019
Tables/Schedules
Allowance for Doubtful Accounts	March 31, 2019 December 31, 2018 Beginning balance $ –– $ 4,000 Additions charged to bad debt expense –– 236 Write off of allowance for doubtful collections –– (4,236 ) Ending balance $ –– $ ––

Accounts Receivable, Net_ Sched

Accounts Receivable, Net: Schedule of Accounts Receivable, Net (Tables)	3 Months Ended
	Mar. 31, 2019
Tables/Schedules
Schedule of Accounts Receivable, Net	March 31, 2019 December 31, 2018 Customer receivables $ 25,180 $ –– Less: allowance for doubtful accounts –– –– Accounts receivable, net $ 25,180 $ ––

Intangible Assets_ Schedule of

Intangible Assets: Schedule of Intangible Assets, Net (Tables)	3 Months Ended
	Mar. 31, 2019
Tables/Schedules
Schedule of Intangible Assets, Net	March 31, 2019 December 31, 2018 Products and processes $ 12,500 $ 12,500 Trademarks and patents / technology 150,700 150,700 Customer lists / relationships 30,000 30,000 Non-compete agreement 30,000 30,000 Marketing related 64,000 64,000 Software 510,300 510,300 Sub-total 797,500 797,500 Accumulated amortization (248,620 ) (218,465 ) Intangible assets, net $ 548,880 $ 579,035

Accounts Payable and Accrued _2

Accounts Payable and Accrued Expenses: Accounts Payable and Accrued Expenses (Tables)	3 Months Ended
	Mar. 31, 2019
Tables/Schedules
Accounts Payable and Accrued Expenses	March 31, 2019 December 31, 2018 Accounts payable-vendors $ 858,218 $ 830,590 Credit cards payable 42,552 42,552 Payroll taxes payable 79,362 78,608 Accrued interest 547,383 450,187 Accrued payroll and payroll taxes 482,047 402,053 Other liabilities 605,148 601,148 2,614,710 2,405,138 Reserve-legal fees 160,000 250,000 Total accounts payable and accrued expenses $ 2,774,710 $ 2,655,138

Notes and Loans Payable_ Schedu

Notes and Loans Payable: Schedule of Notes and Loans Payable (Tables)	3 Months Ended
	Mar. 31, 2019
Tables/Schedules
Schedule of Notes and Loans Payable	March 31, 2019 December 31, 2018 Short-term Debentures, convertible $ 572,535 $ 755,627 Notes payable 20,000 –– Notes payable, convertible , net of unamortized discount 506,913 296,000 Total short-term 1,099,448 1,051,627 Long-term Debentures, convertible, net of unamortized discount 228,150 226,050 Note payable, convertible 720,154 720,154 Note payable-bank 29,058 28,995 Total long-term 977,362 975,199 Total notes and loans payable $ 2,076,810 $ 2,026,826

Notes and Loans Payable_ Non-Re

Notes and Loans Payable: Non-Related Party Convertible Notes Payable (Tables)	3 Months Ended
	Mar. 31, 2019
Tables/Schedules
Non-Related Party Convertible Notes Payable	Holder Principal APR Accrued Interest Conversion Price Term/Due Convertible promissory notes: Short-term Lender Group A $ 120,000 12% to 20% $ 203,460 $0.10 05 /31 Lender Group B 230,913 12% –– $0.10 to $0.12 09 /30 /30 Investor Group A 156,000 10% 23,527 $0.10 09 /30 506,913 226,987 Long-term The Kasper Group, Ltd. 144,000 7% 73,073 $0.10 10 /31 Joseph M. Redmond 576,154 5% 126,653 $0.10 07 /31 720,154 199,726 1,227,067 426,713 Convertible debentures: Short-term 572,535 10% 22,131 $0.12 02 /28 Long-term 250,000 10% –– $0.12 11 /30 Unamortized discount (21,850 ) 10% –– 800,685 22,131 Total convertible debt $ 2,027,752 $ 448,844

Notes and Loans Payable_ Sche_2

Notes and Loans Payable: Schedule of Maturities of Long-term Debt (Tables)	3 Months Ended
	Mar. 31, 2019
Tables/Schedules
Schedule of Maturities of Long-term Debt	Year 2019 2020 2021 Total Principal $720,154 $29,058 $250,000 $999,212

Related Party Transactions_ Sum

Related Party Transactions: Summary (Tables)	3 Months Ended
	Mar. 31, 2019
Tables/Schedules
Summary	March 31, 2019 December 31, 2018 Related party payables: Accrued compensation $ 950,325 $ 869,859 Cash advances 309,533 134,861 Total related party payables 1,259,858 1,004,720 Debentures, convertible 472,470 428,132 Notes payable, convertible, related party 511,100 491,100 Total related party transactions $ 2,243,428 $ 1,923,952

Related Party Transactions_ Rel

Related Party Transactions: Related Party Convertible Debt, By Related Party (Tables)	3 Months Ended
	Mar. 31, 2019
Tables/Schedules
Related Party Convertible Debt, By Related Party	Note Holder Principal APR Accrued Interest Conversion Price Term/Due Convertible promissory notes: Huntington Chase, Beneficial Owner $ 491,100 7% $ 82,537 $0.10 12 /31 John Ogden, Director 20,000 10% –– $0.10 12 /31 $ 511,100 $ 82,537 Convertible debentures: AvantGarde, LLC, Beneficial Owner 393,989 12% 12,729 $0.10 02 /28 Hamburg Investment Co., Beneficial Owner 78,482 12% 2,536 $0.10 02 /28 472,470 15,265 Total convertible debt-related parties $ 983,570 $ 97,802

Warrants And Options_ Warrants

Warrants And Options: Warrants Outstanding (Tables)	3 Months Ended
	Mar. 31, 2019
Tables/Schedules
Warrants Outstanding	Warrants Outstanding Number of Remaining Exercise Price Weighted Common Contractual Life Times Number Average Exercise Price Shares (in years) Of Shares Exercise Price $0.001 300,000 4.25 $ 300 $0.17 $0.01 75,000 1.75 750 $0.19 $0.10 62,500 4.00 6,250 $0.27 $0.10 3,000,000 2.25 300,000 $0.19 $0.10 4,688,750 2.00 468,875 $0.21 $0.10 250,000 1.50 25,000 $0.29 $0.15 300,000 5.00 45,000 $0.17 $0.15 600,000 4.75 90,000 $0.19 $0.15 1,000,000 1.75 150,000 $0.26 $0.17 62,500 4.00 10,625 $0.27 $0.18 62,500 4.00 11,250 $0.27 $0.20 1,300,000 5.00 260,000 $0.18 $0.21 62,500 4.00 13,125 $0.27 $0.21 100,000 1.50 21,000 $0.31 $0.25 3,375,000 2.50 843,750 $0.18 $0.25 475,000 1.75 118,750 $0.25 $0.25 3,255,000 1.50 813,750 $0.29 $0.25 1,500,000 1.25 375,000 $0.34 $0.35 250,000 1.50 87,500 $0.29 $0.60 250,000 1.50 150,000 $0.31 20,968,750 3,790,925 $0.18

Warrants And Options_ Warrant A

Warrants And Options: Warrant Activity (Tables)	3 Months Ended
	Mar. 31, 2019
Tables/Schedules
Warrant Activity	Warrant Activity Weighted Number of Average Shares Exercise Price Outstanding at December 31, 2018 19,668,750 $0.18 Issued 1,600,000 $0.18 Exercised –– –– Expired / Forfeited (300,000 ) $0.18 Outstanding at March 31, 2019 20,968,750 $0.18

Warrants And Options_ Options O

Warrants And Options: Options Outstanding (Tables)	3 Months Ended
	Mar. 31, 2019
Tables/Schedules
Options Outstanding	Options Outstanding Number of Remaining Exercise Price Weighted Common Contractual Life Times Number Average Exercise Price Shares (in years) Of Shares Exercise Price $0.05 90,000 3.25 $ 4,500 $0.14 $0.05 1,140,000 3.00 57,000 $0.09 $0.05 100,000 2.50 5,000 $0.08 $0.05 60,000 1.75 3,000 $0.06 $0.05 170,000 1.50 8,500 $0.12 $0.10 500,000 1.50 50,000 $0.14 $0.10 250,000 0.50 25,000 $0.06 $0.15 1,000,000 1.50 150,000 $0.14 $0.25 1,000,000 4.75 250,000 $0.23 $0.25 5,000,000 4.00 1,250,000 $0.16 $0.25 7,000,000 3.25 1,750,000 $0.16 $0.25 1,000,000 1.50 250,000 $0.15 $0.25 1,000,000 1.00 250,000 $0.10 $0.25 250,000 0.50 62,500 $0.06 $0.35 250,000 0.50 87,500 $0.07 $0.60 250,000 0.50 150,000 $0.08 19,060,000 $ 4,353,000 $0.23

Warrants And Options_ Options A

Warrants And Options: Options Activity (Tables)	3 Months Ended
	Mar. 31, 2019
Tables/Schedules
Options Activity	Options Activity Weighted Number of Average Shares Exercise Price Outstanding at December 31, 2018 18,060,000 $0.23 Issued 1,000,000 $0.23 Exercised –– –– Expired / Forfeited –– –– Outstanding at March 31, 2019 19,060,000 $0.23

Income Taxes_ Schedule of Effec

Income Taxes: Schedule of Effective Income Tax Rate Reconciliation (Tables)	3 Months Ended
	Mar. 31, 2019
Tables/Schedules
Schedule of Effective Income Tax Rate Reconciliation	March 31 2019 December 31, 2018 Income (loss) before taxes $ (1,674,115 ) $ 17,113,718 Statutory rate (Fed & State(s)) 30% 30% Computed expected tax payable (recovery) (422,200 ) 5,230,900 Effect of release of net operating loss carryforwards (927,100 ) (2,738,100 ) Tax effect of non-deductible expenses: Gain on extinguishment of debt-principal –– (6,230,700 ) Stock compensation/amortization of stock options 142,900 1,026,600 Discount amortization 38,900 837,300 Other 800 1,500 Total tax effect of non-deductible expenses 182,600 (4,365,300 ) Change in valuation allowance 1,166,700 (1,872,500 ) Income tax expense $ –– $ –– Reported income taxes: Federal $ –– $ –– State –– –– Total $ –– $ ––

Income Taxes_ Schedule of Compo

Income Taxes: Schedule of Components of Income Tax Expense (Benefit) (Tables)	3 Months Ended
	Mar. 31, 2019
Tables/Schedules
Schedule of Components of Income Tax Expense (Benefit)	March 31, 2019 December 31, 2018 Net operating loss carried forward $ 1,137,500 $ –– Bad debt allowance –– –– Officers’ accrued compensation 265,900 243,400 Accrued related party interest 27,400 20,700 Valuation allowance (1,430,800 ) (264,100 ) Net deferred income tax asset $ –– $ ––

Income Taxes_ Summary of Operat

Income Taxes: Summary of Operating Loss Carryforwards (Tables)	3 Months Ended
	Mar. 31, 2019
Tables/Schedules
Summary of Operating Loss Carryforwards	Tax Year Net Operating Loss Expires 2016 442,900 2036 2017 2,115,400 2037 2018 548,900 No Expiration 2019 to date 957,900 No Expiration Total $ 4,065,100

Discontinued Operations_ Schedu

Discontinued Operations: Schedule of Discontinued Operations, Income Statement (Tables)	3 Months Ended
	Mar. 31, 2019
Tables/Schedules
Schedule of Discontinued Operations, Income Statement	March 31, 2018 Revenue $ –– Cost of sales –– Gross profit –– General and administrative expenses 224,919 Operating loss (224,919 ) Interest expense (21,592 ) Net loss from discontinued operations $ (246,511 )

Segment Reporting_ Schedule of

Segment Reporting: Schedule of Segment Reporting Information, by Segment (Tables)	3 Months Ended
	Mar. 31, 2019
Tables/Schedules
Schedule of Segment Reporting Information, by Segment	. Remote Care Segment Behavioral Health Segment Diagnostics/ Corporate Segment Discontinued Operations Consolidated Totals March 31, 2019 Revenue $ 540 $ 50,450 $ –– –– $ 50,990 Gross profit (loss) (4,571 ) 50,450 –– –– 45,879 Operating loss (86,483 ) (271 ) (1,323,655 ) –– (1,410,409 ) Depreciation and amortization 2,299 27,440 416 –– 30,155 Interest expense 755 –– 99,259 –– 100,014 Loss on settlements –– –– (33,272 ) –– (33,272 ) Discount amortization 8,000 –– 122,420 –– 130,420 Total assets 911,240 437,127 12,407 –– 1,360,774 Goodwill 785,060 –– –– –– 785,060 Additions to property and equipment –– –– –– –– –– March 31, 2018 Revenue 4,440 450 –– –– 4,890 Gross profit (loss) (1,098 ) 450 –– –– (648 ) Operating loss (72,258 ) (126,387 ) (1,753,165 ) –– (1,951,810 ) Depreciation and amortization 2,466 106,775 416 –– 109,657 Interest expense 708 –– 322,442 –– 323,150 Discount amortization 10,000 50,000 1,275,000 –– 1,335,000 Discontinued operations –– –– –– (246,511 ) (246,511 ) Total assets 931,060 2,030,841 13,133 242,454 [1] 3,217,488 Goodwill 785,060 –– –– –– 785,060 Additions to property and equipment –– –– –– –– –– [1] Assets held for sale .

Overview and Nature of Busine_2

Overview and Nature of Business: Going Concern (Details)	Mar. 31, 2019USD ($)
Details
Cumulative Earnings (Deficit)	$ 18,946,375
Working Capital Deficit	$ 5,599,653

Significant Accounting Polici_4

Significant Accounting Policies: Accounts Receivable: Allowance for Doubtful Accounts (Details) - USD ($)	Mar. 31, 2019	Dec. 31, 2018
Details
Allowance, Beginning	$ 0	$ 4,000
Additions charged to bad debt expense	0	236
Write off of allowance for doubtful collections	0	(4,236)
Allowance, Ending Balance	$ 0	$ 0

Significant Accounting Polici_5

Significant Accounting Policies: Accounts Receivable (Details) - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2019	Dec. 31, 2018
Details
Allowance for Doubtful Collections	$ 0	$ 236

Accounts Receivable, Net_ Sch_2

Accounts Receivable, Net: Schedule of Accounts Receivable, Net (Details) - USD ($)	Mar. 31, 2019	Dec. 31, 2018
Details
Accounts Receivable, Gross	$ 25,180	$ 0
Less: Allowance for Doubtful Accounts	0	0
Total Accounts Receivable, Net	$ 25,180	$ 0

Accounts Receivable, Net (Detai

Accounts Receivable, Net (Details) - USD ($)	Mar. 31, 2019	Dec. 31, 2018
Details
Accounts Receivable	$ 25,180	$ 0

Accounts Receivable, Net_ Allow

Accounts Receivable, Net: Allowance For Doubtful Accounts (Details) - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2019	Dec. 31, 2018
Details
Allowance, Increase (decrease)	$ 0	$ 236

Intangible Assets_ Schedule o_2

Intangible Assets: Schedule of Intangible Assets, Net (Details) - USD ($)	Mar. 31, 2019	Dec. 31, 2018
Details
Products and processes	$ 12,500	$ 12,500
Trademarks, patents and technology	150,700	150,700
Customer lists/relationships	30,000	30,000
Non-compete agreement	30,000	30,000
Marketing related intangibles	64,000	64,000
Software	510,300	510,300
Total Intangible Assets, Gross	797,500	797,500
Accumulated amortization	(248,620)	(218,465)
Intangible Assets, Net	$ 548,880	$ 579,035

Intangible Assets_ Amortization

Intangible Assets: Amortization Expense (Details) - USD ($)	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Details
Amortization Expense	$ 30,155	$ 120,620

Accounts Payable and Accrued _3

Accounts Payable and Accrued Expenses: Summary (Details) - USD ($)	Mar. 31, 2019	Dec. 31, 2018
Details
Accounts Payable, Vendors	$ 858,218	$ 830,590
Credit cards payable	42,552	42,552
Payroll taxes payable	79,362	78,608
Accrued Interest	547,383	450,187
Accrued payroll and payroll taxes	482,047	402,053
Other liabilities	605,148	601,148
Reserve-Legal Fees	160,000	250,000
Total accounts payable and accrued expenses	$ 2,774,710	$ 2,655,138

Accounts Payable and Accrued _4

Accounts Payable and Accrued Expenses: Payroll Taxes Payable (Details) - USD ($)	Mar. 31, 2019	Dec. 31, 2018
Details
Payroll Taxes Payable, Penalties	$ 17,476	$ 17,476
Payroll Taxes Payable, Interest	$ 4,957	$ 4,202

Accounts Payable and Accrued _5

Accounts Payable and Accrued Expenses: Other Liabilities (Details) - USD ($)	Mar. 31, 2019	Dec. 31, 2018
Details
Payroll Taxes-RoxSan Pharmacy	$ 501,148	$ 601,148
Litigation Settlement	$ 104,000	$ 0

Accounts Payable and Accrued _6

Accounts Payable and Accrued Expenses: Extinguishment of Debt (Details)	3 Months Ended
	Mar. 31, 2019USD ($)
Extinguishment of Debt	$ 341,606
Accounts Payable
Extinguishment of Debt	284,714
Accrued Interest
Extinguishment of Debt	$ 56,892

Accounts Payable and Accrued _7

Accounts Payable and Accrued Expenses: Legal Fees Reserve (Details) - USD ($)	Mar. 31, 2019	Dec. 31, 2018
Details
Reserve-Legal Fees-Current Period Adjustment	$ 90,000	$ 0
Reserve-Legal Fees	$ 160,000	$ 250,000

Notes and Loans Payable_ Summar

Notes and Loans Payable: Summary (Details) - USD ($)	Mar. 31, 2019	Dec. 31, 2018
Details
Debentures, Convertible	$ 572,535	$ 755,627
Notes payable	20,000	0
Convertible Notes Payable, Current	506,913	296,000
Total short-term	1,099,448	1,051,627
Debentures, Convertible, Net of Unamortized Discount	228,150	226,050
Notes Payable, Convertible	720,154	720,154
Note Payable-Bank	29,058	28,995
Total long-term	977,362	975,199
Notes Payable, Total	$ 2,076,810	$ 2,026,826

Notes and Loans Payable_ Non-_2

Notes and Loans Payable: Non-Related Party Convertible Notes Payable (Details)	3 Months Ended
	Mar. 31, 2019USD ($)$ / shares
Lender Group A
Principal	$ 120,000
Accrued Interest	$ 203,460
Conversion Price | $ / shares	$ 0.10
Term/Due	May 31, 2018
Lender Group B
Principal	$ 230,913
APR	12.00%
Accrued Interest	$ 0
Lender Group B | Minimum
Conversion Price | $ / shares	$ 0.10
Lender Group B | Maximum
Conversion Price | $ / shares	$ 0.12
Investor Group A
Principal	$ 156,000
APR	10.00%
Accrued Interest	$ 23,527
Conversion Price | $ / shares	$ 0.10
Term/Due	Sep. 30, 2018
The Kasper Group, Ltd
Principal	$ 144,000
APR	7.00%
Accrued Interest	$ 73,073
Conversion Price | $ / shares	$ 0.10
Term/Due	Oct. 31, 2019
Joseph M. Redmond
Principal	$ 576,154
APR	5.00%
Accrued Interest	$ 126,653
Conversion Price | $ / shares	$ 0.10
Term/Due	Jul. 31, 2017
Short-term Debentures
Principal	$ 572,535
APR	10.00%
Accrued Interest	$ 22,131
Conversion Price | $ / shares	$ 0.12
Term/Due	Feb. 28, 2019
Long-term Debentures
Principal	$ 250,000
APR	10.00%
Accrued Interest	$ 0
Conversion Price | $ / shares	$ 0.12
Term/Due	Nov. 30, 2021
Long-term Debentures, Unamortized Discount
Principal	$ (21,850)
APR	10.00%
Accrued Interest	$ 0
Principal	2,027,752
Accrued Interest	$ 448,844

Notes and Loans Payable_ Short-

Notes and Loans Payable: Short-Term Debt (Details) - USD ($)	Mar. 31, 2019	Dec. 31, 2018
Details
Short-Term Debt, Total	$ 1,099,448	$ 1,051,627
Short-Term Debt, Debentures, Convertible	572,155	755,627
Short-Term Debt, Notes Payable	20,000	0
Short-Term Debt, Notes Payable, Convertible	506,913	296,000
Short-Term Debt, Repayments, Cash	0	50,000
Short-Term Debt, Repayments, Conversions	20,000	620,000
Short-Term Debt, Repayments, Conversions, Interest	2,000	55,613
Short-Term Debt, Accrued Interest, Current	65,377	370,650
Short-Term Debt, Accrued Interest, Total	$ 249,118	$ 185,741

Notes and Loans Payable_ Long-T

Notes and Loans Payable: Long-Term Debt (Details) - USD ($)	Mar. 31, 2019	Dec. 31, 2018
Details
Long-Term Debt, Total	$ 977,362	$ 975,199
Long-Term Debt, Debentures, Convertible	250,000	250,000
Long-Term Debt, Debentures, Convertible, Discount	21,850	23,950
Long-Term Debt, Notes Payable, Convertible	720,154	720,154
Long-Term Debt, Notes Payable, Banks	29,058	28,995
Long-Term Debt, Debentures, Convertible, Discount, Amortization	2,100	1,050
Long-Term Debt, Accrued Interest, Current	10,139	40,956
Long-Term Debt, Accrued Interest, Total	$ 200,462	$ 40,956

Notes and Loans Payable_ Future

Notes and Loans Payable: Future Maturities of Long-Term Debt (Details)	Mar. 31, 2019USD ($)
2019
Long-Term Debt, Principal	$ 720,154
2020
Long-Term Debt, Principal	29,058
2021
Long-Term Debt, Principal	250,000
Long-Term Debt, Principal	$ 999,212

Notes and Loans Payable_ Accrue

Notes and Loans Payable: Accrued Interest (Details) - USD ($)	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Dec. 31, 2018
Details
Accrued Interest, Current Period	$ 75,516	$ 40,956
Accrued Interest	$ 449,580		$ 376,127

Related Party Transactions_ S_2

Related Party Transactions: Summary (Details) - USD ($)	Mar. 31, 2019	Dec. 31, 2018
Related party payables
Related Party, Accrued Compensation	$ 950,325	$ 869,859
Related Party, Cash Advances	309,533	134,861
Related Party, Total Payables	1,259,858	1,004,720
Debentures, convertible	472,470	428,132
Notes payable, convertible, related party	511,100	491,100
Total Related Party Trasactions	$ 2,243,428	$ 1,923,952

Related Party Transactions_ Con

Related Party Transactions: Convertible Debt (Details)	3 Months Ended
	Mar. 31, 2019USD ($)
Beneficial Owner
Note Payable, Convertible, Related Party, Principal	$ 491,100
Note Payable, Convertible, Related Party, Interest Rate	7.00%
Note Payable, Convertible, Related Party, Accrued Interest	$ 82,537
Note Payable, Convertible, Related Party, Conversion Price	$ 0.10
Note Payable, Convertible, Related Party, Maturity Date	Dec. 31, 2023
DIrector
Note Payable, Convertible, Related Party, Principal	$ 20,000
Note Payable, Convertible, Related Party, Interest Rate	10.00%
Note Payable, Convertible, Related Party, Accrued Interest	$ 0
Note Payable, Convertible, Related Party, Conversion Price	$ 0.10
Note Payable, Convertible, Related Party, Maturity Date	Dec. 31, 2019
Beneficial Owner
Note Payable, Convertible, Related Party, Principal	$ 393,989
Note Payable, Convertible, Related Party, Interest Rate	12.00%
Note Payable, Convertible, Related Party, Accrued Interest	$ 12,729
Note Payable, Convertible, Related Party, Conversion Price	$ 0.10
Note Payable, Convertible, Related Party, Maturity Date	Feb. 28, 2019
Beneficial Owner
Note Payable, Convertible, Related Party, Principal	$ 78,482
Note Payable, Convertible, Related Party, Interest Rate	12.00%
Note Payable, Convertible, Related Party, Accrued Interest	$ 2,536
Note Payable, Convertible, Related Party, Conversion Price	$ 0.10
Note Payable, Convertible, Related Party, Maturity Date	Feb. 28, 2019
Note Payable, Convertible, Related Party, Principal	$ 983,570
Note Payable, Convertible, Related Party, Accrued Interest	$ 97,802

Related Party Transactions_ S_3

Related Party Transactions: Summary Totals (Details) - USD ($)	Mar. 31, 2019	Dec. 31, 2018
Details
Related Party Transactions, Total	$ 2,243,428	$ 1,923,952
Related Party Transactions, Accrued Compensation	950,325	869,859
Related Party Transactions, Advances to Company	309,533	134,861
Related Party Transactions, Convertible Debentures	472,470	428,132
Related Party Transactions, Convertible Notes Payable	$ 511,100	$ 491,100

Related Party Transactions_ Acc

Related Party Transactions: Accrued Interest (Details) - USD ($)	Mar. 31, 2019	Dec. 31, 2018
Details
Related Party Transactions, Accrued Interest, Current	$ 23,742	$ 123,133
Related Party Transactions, Accrued Interest, Paid	0	(798)
Related Party Transactions, Accrued Interest, To Principal	0	(128,132)
Related Party Transactions, Accrued Interest, Total	$ 97,802	$ 74,060

Commitments And Contingencies (

Commitments And Contingencies (Details) - USD ($)	3 Months Ended
	Mar. 31, 2019	Dec. 31, 2018
Qolpom Shareholders
Contingency, Revenue Share, Maximum Payment	$ 2,000,000
Contingency, Royalty, Percent	3.00%
Contingency, Revenue Share, Present Value	$ 433,000	$ 430,000
Contingency, Royalty, Present Value	315,000	310,000
ProEventa
Contingency, Revenue Share, Maximum Payment	$ 3,000,000
Contingency, Royalty, Percent	3.00%
Contingency, Revenue Share, Present Value	$ 1,042,000	1,040,000
Contingency, Royalty, Present Value	693,000	690,000
Contingency, Royalty, Maximum Payment	25,000,000
Payable, Royalties	2,700	$ 0
Pending Litigation
Gain Contingency, Promissory Note, Principal	20,500,000
Gain Contingency, Promissory Note, Accrued Interest	2,278,281
Gain Contingency, Promissory Note, Total	$ 22,778,281
Secured Debt, In Litigation
Note Payable, Date	Aug. 13, 2015
Note Payable, Principal	$ 20,500,000
Note Payable, Interest Rate	6.00%
Note Payable, Maturity Date	Aug. 13, 2018

Convertible Preferred Stock (De

Convertible Preferred Stock (Details) - $ / shares	Mar. 31, 2019	Dec. 31, 2018
Preferred Stock, Shares Authorized	10,000,000	10,000,000
Preferred Stock, Par or Stated Value Per Share	$ 0.001	$ 0.001
Preferred Stock, Shares Outstanding	977,352	1,013,691
Preferred Stock
Preferred Stock, Shares Outstanding	977,352	1,013,691

Convertible Preferred Stock_ Ac

Convertible Preferred Stock: Activity (Details) - Series A Preferred Stock	Mar. 31, 2019USD ($)shares
Preferred Stock, Cancelled, Treasury Shares | shares	36,339
Preferred Stock, Cancelled, Treasury Shares	$ 100,000
Preferred Stock, Cancelled, Paid in Capital	$ 99,964

Common Stock (Details)

Common Stock (Details) - $ / shares	Mar. 31, 2019	Dec. 31, 2018
Common Stock, Shares Authorized	500,000,000	250,000,000
Common Stock, Par or Stated Value Per Share	$ 0.001	$ 0.001
Common Stock, Shares, Outstanding	170,259,136	158,113,141
Common Class A
Common Stock, Shares Authorized	500,000,000	250,000,000
Common Stock, Par or Stated Value Per Share	$ 0.001	$ 0.001
Common Stock, Shares, Outstanding	170,259,136	158,113,141

Common Stock_ Activity (Details

Common Stock: Activity (Details)	Mar. 31, 2019
Common Stock, Shares, Issued
Shares Issued, Conversion of Debt	3,689,328
Shares Issued, Stock Awards	2,716,667
Shares Issued, SAFE offering	5,000,000
Shares Issued, Debt Service	740,000
Common Stock, Conversion of Debt, Amount
Shares Issued, Conversion of Debt	292,000
Common Stock, APIC
Shares Issued, Conversion of Debt	288,311
Shares Issued, Stock Awards	322,283
Shares Issued, SAFE offering	495,000
Shares Issued, Debt Service	73,260
Common Stock, Shares, Value
Shares Issued, Stock Awards	325,000
Shares Issued, SAFE offering	500,000
Shares Issued, Debt Service	74,000

Common Stock_ Deferred Compensa

Common Stock: Deferred Compensation (Details)	3 Months Ended	12 Months Ended
	Mar. 31, 2019USD ($)shares	Dec. 31, 2018USD ($)shares
Details
Stock Issued During Period, Shares, Period Increase (Decrease) | shares	12,145,995	21,358,611
Deferred Compensation, Total	$ 74,000	$ 434,000
Deferred Compensation, Current Expense	124,357	1,095,193
Deferred Compensation, Future Expense	$ 1,098,452	$ 1,148,809
Deferred Compensation, Future Expense, Term (Months)	19

Warrants And Options_ Issued an

Warrants And Options: Issued and Outstanding (Details) - shares	Mar. 31, 2019	Dec. 31, 2018
Details
Warrants, Number of Shares	20,968,750	19,668,750
Stock Options, Number of Shares	19,060,000	18,060,000

Warrants And Options_ Activity-

Warrants And Options: Activity-Warrants (Details)	3 Months Ended	12 Months Ended
	Mar. 31, 2019$ / shares	Dec. 31, 2018
Warrants, Granted	1,600,000	12,513,750
Warrants, Expired	300,000	100,000
Minimum
Warrants, Exercise Price	$ 0.001
Warrants, Expiration (Year)	2019
Maximum
Warrants, Exercise Price	$ 0.600
Warrants, Expiration (Year)	2023

Warrants And Options_ Schedule

Warrants And Options: Schedule of Warrants Outstanding (Details)	3 Months Ended
	Mar. 31, 2019USD ($)$ / sharesshares
$0.001
Warrants, Number of Shares | shares	300,000
Warrants, Remaining Life (Years)	4 years 3 months
Warrants, Exercise Price X Number Of Shares | $	$ 300
Warrants, Weighted Average Exercise Price | $ / shares	$ 0.17
$0.10
Warrants, Number of Shares | shares	75,000
Warrants, Remaining Life (Years)	1 year 9 months
Warrants, Exercise Price X Number Of Shares | $	$ 750
Warrants, Weighted Average Exercise Price | $ / shares	$ 0.19
$0.10
Warrants, Number of Shares | shares	62,500
Warrants, Remaining Life (Years)	4 years
Warrants, Exercise Price X Number Of Shares | $	$ 6,250
Warrants, Weighted Average Exercise Price | $ / shares	$ 0.27
$0.10
Warrants, Number of Shares | shares	3,000,000
Warrants, Remaining Life (Years)	2 years 3 months
Warrants, Exercise Price X Number Of Shares | $	$ 300,000
Warrants, Weighted Average Exercise Price | $ / shares	$ 0.19
$0.10
Warrants, Number of Shares | shares	4,688,750
Warrants, Remaining Life (Years)	2 years
Warrants, Exercise Price X Number Of Shares | $	$ 468,875
Warrants, Weighted Average Exercise Price | $ / shares	$ 0.21
$0.10
Warrants, Number of Shares | shares	250,000
Warrants, Remaining Life (Years)	1 year 6 months
Warrants, Exercise Price X Number Of Shares | $	$ 25,000
Warrants, Weighted Average Exercise Price | $ / shares	$ 0.29
$0.15
Warrants, Number of Shares | shares	300,000
Warrants, Remaining Life (Years)	5 years
Warrants, Exercise Price X Number Of Shares | $	$ 45,000
Warrants, Weighted Average Exercise Price | $ / shares	$ 0.17
$0.15
Warrants, Number of Shares | shares	600,000
Warrants, Remaining Life (Years)	4 years 9 months
Warrants, Exercise Price X Number Of Shares | $	$ 90,000
Warrants, Weighted Average Exercise Price | $ / shares	$ 0.19
$0.15
Warrants, Number of Shares | shares	1,000,000
Warrants, Remaining Life (Years)	1 year 9 months
Warrants, Exercise Price X Number Of Shares | $	$ 150,000
Warrants, Weighted Average Exercise Price | $ / shares	$ 0.26
$0.17
Warrants, Number of Shares | shares	62,500
Warrants, Remaining Life (Years)	4 years
Warrants, Exercise Price X Number Of Shares | $	$ 10,625
Warrants, Weighted Average Exercise Price | $ / shares	$ 0.27
$0.18
Warrants, Number of Shares | shares	62,500
Warrants, Remaining Life (Years)	4 years
Warrants, Exercise Price X Number Of Shares | $	$ 11,250
Warrants, Weighted Average Exercise Price | $ / shares	$ 0.27
$0.20
Warrants, Number of Shares | shares	1,300,000
Warrants, Remaining Life (Years)	5 years
Warrants, Exercise Price X Number Of Shares | $	$ 260,000
Warrants, Weighted Average Exercise Price | $ / shares	$ 0.18
$0.21
Warrants, Number of Shares | shares	62,500
Warrants, Remaining Life (Years)	4 years
Warrants, Exercise Price X Number Of Shares | $	$ 13,125
Warrants, Weighted Average Exercise Price | $ / shares	$ 0.27
$0.21
Warrants, Number of Shares | shares	100,000
Warrants, Remaining Life (Years)	1 year 6 months
Warrants, Exercise Price X Number Of Shares | $	$ 21,000
Warrants, Weighted Average Exercise Price | $ / shares	$ 0.31
$0.25
Warrants, Number of Shares | shares	3,375,000
Warrants, Remaining Life (Years)	2 years 6 months
Warrants, Exercise Price X Number Of Shares | $	$ 843,750
Warrants, Weighted Average Exercise Price | $ / shares	$ 0.18
$0.25
Warrants, Number of Shares | shares	475,000
Warrants, Remaining Life (Years)	1 year 9 months
Warrants, Exercise Price X Number Of Shares | $	$ 118,750
Warrants, Weighted Average Exercise Price | $ / shares	$ 0.25
$0.25
Warrants, Number of Shares | shares	3,255,000
Warrants, Remaining Life (Years)	1 year 6 months
Warrants, Exercise Price X Number Of Shares | $	$ 813,750
Warrants, Weighted Average Exercise Price | $ / shares	$ 0.29
$0.25
Warrants, Number of Shares | shares	1,500,000
Warrants, Remaining Life (Years)	1 year 3 months
Warrants, Exercise Price X Number Of Shares | $	$ 375,000
Warrants, Weighted Average Exercise Price | $ / shares	$ 0.34
$0.35
Warrants, Number of Shares | shares	250,000
Warrants, Remaining Life (Years)	1 year 6 months
Warrants, Exercise Price X Number Of Shares | $	$ 87,500
Warrants, Weighted Average Exercise Price | $ / shares	$ 0.29
$0.60
Warrants, Number of Shares | shares	250,000
Warrants, Remaining Life (Years)	1 year 6 months
Warrants, Exercise Price X Number Of Shares | $	$ 150,000
Warrants, Weighted Average Exercise Price | $ / shares	$ 0.31
Warrants, Number of Shares | shares	20,968,750
Warrants, Exercise Price X Number Of Shares | $	$ 3,790,925
Warrants, Weighted Average Exercise Price | $ / shares	$ 0.18

Warrants And Options_ Warrant R

Warrants And Options: Warrant Rollforward (Details)	3 Months Ended
	Mar. 31, 2019USD ($)$ / sharesshares
Details
Warrants, Outstanding, Beginnning	19,668,750
Warrants, Outstanding, Beginning, Weighted Avg Exercise Price | $ / shares	$ 0.18
Warrants, Issued in Period	1,600,000
Warrants, Issued in Period, Weighted Avg Exercise Price | $ / shares	$ 0.18
Warrants, Exercised in Period	0
Warrants, Exercised in Period, Weighted Avg Exercise Price | $ / shares	$ 0
Warrants, Expired/Cancelled in Period	(300,000)
Warrants, Expired/Cancelled in Period, Weighted Avg Exercise Price | $ / shares	$ 0.18
Warrants, Outstanding, Ending	20,968,750
Warrants, Outstanding, Ending, Weighted Avg Exercise Price | $	$ 0.18

Warrants And Options_ Current P

Warrants And Options: Current Period Grants (Details)	3 Months Ended	12 Months Ended
	Mar. 31, 2019USD ($)$ / sharesshares	Dec. 31, 2018USD ($)shares
Stock Options, Granted | shares	1,000,000	6,000,000
Stock Options, Vest Period (Years)	2
Stock Options, Value | $	$ 96,100	$ 833,700
Stock Options, Yield	0.00%
Minimum
Stock Options, Life (Years)	3
Stock Options, Exercise Price	$ 0.05
Stock Options, Expected Term (Years)	3
Stock Options, Expected Volatility	1.82
Stock Options, Risk Free Interest Rate	2.25%
Maximum
Stock Options, Life (Years)	5
Stock Options, Exercise Price	$ 0.50
Stock Options, Expected Term (Years)	3.75
Stock Options, Expected Volatility	2.29
Stock Options, Risk Free Interest Rate	2.78%

Warrants And Options_ Options_2

Warrants And Options: Options Outstanding (Details)	3 Months Ended
	Mar. 31, 2019USD ($)$ / sharesshares
$0.05
Stock Options, Number of Shares | shares	90,000
Stock Options, Remaining Life (Years)	3 years 3 months
Stock Options, Exercise Price x Number of Shares | $	$ 4,500
Stock Options, Weighted Average Exercise Price | $ / shares	$ 0.14
$0.05
Stock Options, Number of Shares | shares	1,140,000
Stock Options, Remaining Life (Years)	3 years
Stock Options, Exercise Price x Number of Shares | $	$ 57,000
Stock Options, Weighted Average Exercise Price | $ / shares	$ 0.09
$0.05
Stock Options, Number of Shares | shares	100,000
Stock Options, Remaining Life (Years)	2 years 6 months
Stock Options, Exercise Price x Number of Shares | $	$ 5,000
Stock Options, Weighted Average Exercise Price | $ / shares	$ 0.08
$0.05
Stock Options, Number of Shares | shares	60,000
Stock Options, Remaining Life (Years)	1 year 9 months
Stock Options, Exercise Price x Number of Shares | $	$ 3,000
Stock Options, Weighted Average Exercise Price | $ / shares	$ 0.06
$0.05
Stock Options, Number of Shares | shares	170,000
Stock Options, Remaining Life (Years)	1 year 6 months
Stock Options, Exercise Price x Number of Shares | $	$ 8,500
Stock Options, Weighted Average Exercise Price | $ / shares	$ 0.12
$0.10
Stock Options, Number of Shares | shares	500,000
Stock Options, Remaining Life (Years)	1 year 6 months
Stock Options, Exercise Price x Number of Shares | $	$ 50,000
Stock Options, Weighted Average Exercise Price | $ / shares	$ 0.14
$0.10
Stock Options, Number of Shares | shares	250,000
Stock Options, Remaining Life (Years)	6 months
Stock Options, Exercise Price x Number of Shares | $	$ 25,000
Stock Options, Weighted Average Exercise Price | $ / shares	$ 0.06
$0.15
Stock Options, Number of Shares | shares	1,000,000
Stock Options, Remaining Life (Years)	1 year 6 months
Stock Options, Exercise Price x Number of Shares | $	$ 150,000
Stock Options, Weighted Average Exercise Price | $ / shares	$ 0.14
$0.25
Stock Options, Number of Shares | shares	1,000,000
Stock Options, Remaining Life (Years)	4 years 9 months
Stock Options, Exercise Price x Number of Shares | $	$ 250,000
Stock Options, Weighted Average Exercise Price | $ / shares	$ 0.23
$0.25
Stock Options, Number of Shares | shares	5,000,000
Stock Options, Remaining Life (Years)	4 years
Stock Options, Exercise Price x Number of Shares | $	$ 1,250,000
Stock Options, Weighted Average Exercise Price | $ / shares	$ 0.16
$0.25
Stock Options, Number of Shares | shares	7,000,000
Stock Options, Remaining Life (Years)	3 years 3 months
Stock Options, Exercise Price x Number of Shares | $	$ 1,750,000
Stock Options, Weighted Average Exercise Price | $ / shares	$ 0.16
$0.25
Stock Options, Number of Shares | shares	1,000,000
Stock Options, Remaining Life (Years)	1 year 6 months
Stock Options, Exercise Price x Number of Shares | $	$ 250,000
Stock Options, Weighted Average Exercise Price | $ / shares	$ 0.15
$0.25
Stock Options, Number of Shares | shares	1,000,000
Stock Options, Remaining Life (Years)	1 year
Stock Options, Exercise Price x Number of Shares | $	$ 250,000
Stock Options, Weighted Average Exercise Price | $ / shares	$ 0.10
$0.25
Stock Options, Number of Shares | shares	250,000
Stock Options, Remaining Life (Years)	6 months
Stock Options, Exercise Price x Number of Shares | $	$ 62,500
Stock Options, Weighted Average Exercise Price | $ / shares	$ 0.06
$0.35
Stock Options, Number of Shares | shares	250,000
Stock Options, Remaining Life (Years)	6 months
Stock Options, Exercise Price x Number of Shares | $	$ 87,500
Stock Options, Weighted Average Exercise Price | $ / shares	$ 0.07
$0.60
Stock Options, Number of Shares | shares	250,000
Stock Options, Remaining Life (Years)	6 months
Stock Options, Exercise Price x Number of Shares | $	$ 150,000
Stock Options, Weighted Average Exercise Price | $ / shares	$ 0.08
Stock Options, Number of Shares | shares	19,060,000
Stock Options, Exercise Price x Number of Shares | $	$ 4,353,000
Stock Options, Weighted Average Exercise Price | $ / shares	$ 0.23

Warrants And Options_ Options R

Warrants And Options: Options Rollforward (Details) - $ / shares	3 Months Ended	12 Months Ended
	Mar. 31, 2019	Dec. 31, 2018
Details
Stock Options, Beginning	18,060,000
Stock Options, Beginning, Weighted Average Exercise Price	$ 0.23
Stock Options, Grants In Period	1,000,000	6,000,000
Stock Options, Grants in Period, Weighted Average Exercise Price	$ 0.23
Stock Options, Exercises	0
Stock Options, Exercises in Period, Weighted Average Exercise Price	$ 0
Stock Options, Expirations/Forfeitures in Period	0
Stock Options, Expirations/Forfeitures in Period, Weighted Average Exercise Price	$ 0
Stock Options, Ending	19,060,000	18,060,000
Stock Options, Ending, Weighted Average Exercise Price	$ 0.23	$ 0.23

Warrants And Options_ Activit_2

Warrants And Options: Activity-Options (Details) - shares	3 Months Ended	12 Months Ended
	Mar. 31, 2019	Dec. 31, 2018
Details
Stock Options, Grants	1,000,000	6,000,000
Stock Options, Exercises	0	1,973,189
Stock Options, Expirations	0	1,000,000
Stock Options, Forfeitures	0	5,641,811

Warrants And Options_ Deferred

Warrants And Options: Deferred Stock Option Compensation (Details)	3 Months Ended	12 Months Ended
	Mar. 31, 2019USD ($)	Dec. 31, 2018USD ($)
Details
Deferred Compensation, Total	$ 96,100	$ 649,327
Deferred Compensation, Current Period Expense	29,442	572,870
Deferred Compensation, Future Expense	$ 1,462,124	$ 1,395,466
Deferred Compensation, Future Expense, Term (Months)	21

Leases (Details)

Leases (Details)	3 Months Ended
	Mar. 31, 2019USD ($)
Santa Monica, CA
Office Lease, Rent Expense, Base, Monthly	$ 5,600

Leases_ Rent Expense (Details)

Leases: Rent Expense (Details) - USD ($)	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Details
Office Lease, Rent Expense, Base	$ 17,360	$ 19,397

Income Taxes_ Schedule of Eff_2

Income Taxes: Schedule of Effective Income Tax Rate Reconciliation (Details) - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2019	Dec. 31, 2018
Details
Income (Loss) from Continuing Operations before Income Taxes, Domestic	$ (1,674,115)	$ 17,113,718
Statutory Rate (Fed & State(s))	30.00%	30.00%
Computed Expected Tax Payable (Recovery)	$ (422,200)	$ 5,230,900
Effect of release of net operating loss carryforwards	(927,100)	(2,738,100)
Gain on extinguishment of debt-principal	0	(6,230,700)
Non-Deductible, Stock Option Amortization	142,900	1,026,600
Non-Deductible, Discount amortization	38,900	837,300
Non-Deductible, Other	800	1,500
Non-Deductible, Total	182,600	(4,365,300)
Change in Valuation Allowance	1,166,700	(1,872,500)
Current Income Tax Expense (Benefit)	0	0
Reported Income Taxes, Federal	0	0
Reported Income Taxes, State	0	0
Reported Income Taxes, Total	$ 0	$ 0

Income Taxes_ Schedule of Com_2

Income Taxes: Schedule of Components of Income Tax Expense (Benefit) (Details) - USD ($)	Mar. 31, 2019	Dec. 31, 2018
Details
Deferred Tax Asset, Net Operating Losses	$ 1,137,500	$ 0
Deferred Tax Asset, Bad Debt Allowance	0	0
Deferred Tax Asset, Officers Accrued Compensation	265,900	243,400
Deferred Tax Asset, Related Party Interest	27,400	20,700
Deferred Tax Asset, Valuation Allowance	(1,430,800)	(264,100)
Deferred Tax Assets, Net of Valuation Allowance	$ 0	$ 0

Income Taxes (Details)

Income Taxes (Details)	3 Months Ended
	Mar. 31, 2019USD ($)
Details
Extinguishment of Debt, Pricipal	$ 20,880,688
Operating Loss Carryforwards	$ 4,065,100
Years Open to Examination, Beginning Year	2011

Income Taxes_ Summary of Oper_2

Income Taxes: Summary of Operating Loss Carryforwards (Details)	3 Months Ended
	Mar. 31, 2019USD ($)
2016
Operating Loss Carryforwards	$ 442,900
NOL Expiration (Year)	2036
2017
Operating Loss Carryforwards	$ 2,115,400
NOL Expiration (Year)	2037
2018
Operating Loss Carryforwards	$ 548,900
2019
Operating Loss Carryforwards	957,900
Operating Loss Carryforwards	$ 4,065,100

Discontinued Operations (Detail

Discontinued Operations (Details)	Dec. 31, 2018USD ($)
Payroll Taxes Payable	$ 1,148,811
RoxSan Pharamcy Inc
Payroll Taxes Payable	601,148
Payroll Taxes Payable, Penalties	183,172
Payroll Taxes Payable, Interest	364,491
Gain on Deconsolidation	4,478,268
Gain on extinguishment of debt	$ 22,778,281

Discontinued Operations_ Sche_2

Discontinued Operations: Schedule of Discontinued Operations, Income Statement (Details) - RoxSan Pharamcy Inc	3 Months Ended
	Mar. 31, 2019USD ($)
Revenue	$ 0
Cost of Goods Sold	0
Gross Profit	0
General & Administrative Expenses	224,919
Operating Loss	(224,919)
Interest Expense	(21,592)
Net Loss	$ (246,511)

Segment Reporting_ Schedule o_2

Segment Reporting: Schedule of Segment Reporting Information, by Segment (Details) - USD ($)	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Revenue	$ 50,990	$ 4,890
Gross Profit	45,879	(648)
Operating Income (loss)	(1,410,409)	(1,951,810)
Deprecation and amortization	30,155	109,657
Interest Expense	100,014	323,150
Loss on settlements	(33,272)	0
Discount Amortization	130,420	1,335,000
Total Assets	1,360,774	3,217,488
Goodwill	785,060	785,060
Additions to Property and Equipment	0	0
Discontinued operations		(246,511)
Remote Care Segment
Revenue	540	4,440
Gross Profit	(4,571)	(1,098)
Operating Income (loss)	(86,483)	(72,258)
Deprecation and amortization	2,299	2,466
Interest Expense	755	708
Loss on settlements	0
Discount Amortization	8,000	10,000
Total Assets	911,240	931,060
Goodwill	785,060	785,060
Additions to Property and Equipment	0	0
Discontinued operations		0
Behavioral Healthcare Segment
Revenue	50,450	450
Gross Profit	50,450	450
Operating Income (loss)	(271)	(126,387)
Deprecation and amortization	27,440	106,775
Interest Expense	0	0
Loss on settlements	0
Discount Amortization	0	50,000
Total Assets	437,127	2,030,841
Goodwill	0	0
Additions to Property and Equipment	0	0
Discontinued operations		0
Diagnostics/Corporate Segment
Revenue	0	0
Gross Profit	0	0
Operating Income (loss)	(1,323,655)	(1,753,165)
Deprecation and amortization	416	416
Interest Expense	99,259	322,442
Loss on settlements	(33,272)
Discount Amortization	122,420	1,275,000
Total Assets	12,407	13,133
Goodwill	0	0
Additions to Property and Equipment	0	0
Discontinued operations		0
Pharmacy Segment
Revenue	0	0
Gross Profit	0	0
Operating Income (loss)	0	0
Deprecation and amortization	0	0
Interest Expense	0	0
Loss on settlements	0
Discount Amortization	0	0
Total Assets	0	242,454
Goodwill	0	0
Additions to Property and Equipment	$ 0	0
Discontinued operations		$ (246,511)

Legal Matters (Details)

Legal Matters (Details) - USD ($)	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Details
Loss on settlements	$ 33,272	$ 0

Subsequent Events (Details)

Subsequent Events (Details)	3 Months Ended
	Mar. 31, 2019USD ($)$ / sharesshares
Convertible Promissory Note
Convertible Promissory Note, Interest Rate	12.00%
Convertible Promissory Note, Principal	$ 214,000
Convertible Promissory Note, Maturity	Apr. 2, 2020
Convertible Promissory Note, Conversion Price | $ / shares	$ 0.12
Convertible Promissory Note, Conversion Price, Discount	65.00%
Convertible Promissory Note, Warrants | shares	300,000
Convertible Promissory Note, Warrants, Exercise Price | $ / shares	$ 0.15
Convertible Promissory Note, Warrants, Term (Yrs)	5
Conversion of Debt
Stock Issuance, Debt Conversion, Amount	$ 105,000
Stock Issuance, Debt Conversion, Shares | shares	2,340,410
Stock Issuance, Debt Conversion, Paid In Capital	$ 102,660
Stock Issuance, Services
Stock Issuance, For Services, Shares | shares	825,000
Stock Issuance, For Services, Value	$ 80,500
Stock Issuance, For Services, Paid In Capital	$ 79,675
Employment Agreement, Chief Operating Officer
Employment Agreement, Effective Date	May 15, 2019
Employment Agreement, Term	2
Employment Agreement, Compensation, Year 1	$ 250,000
Employment Agreement, Compensation, Year 2	$ 275,000
Employment Agreement, Stock Award, Shares | shares	3,000,000
Employment Agreement, Stock Award, Price Per Share | $ / shares	$ 0.001
Employment Agreement, Stock Award, Initial Vesting (Pct)	25.00%
Employment Agreement, Stock Options, Shares | shares	3,000,000
Employment Agreement, Stock Options, Exercise Price | $ / shares	$ 0.25
Employment Agreement, Stock Options, Term (Yrs)	5
Employment Agreement, Stock Options, Initial Vesting (Pct)	25.00%
Employment Agreement, Chief Legal Officer
Employment Agreement, Effective Date	May 15, 2019
Employment Agreement, Term	2
Employment Agreement, Compensation, Year 1	$ 130,000
Employment Agreement, Compensation, Year 2	$ 140,000
Employment Agreement, Stock Award, Price Per Share | $ / shares	$ 0.001
Employment Agreement, Stock Award, Initial Vesting (Pct)	25.00%
Employment Agreement, Stock Options, Shares | shares	500,000
Employment Agreement, Stock Options, Exercise Price | $ / shares	$ 0.25
Employment Agreement, Stock Options, Term (Yrs)	5
Employment Agreement, Stock Options, Initial Vesting (Pct)	25.00%
Office Lease
Office Lease, Date	May 1, 2019
Office Lease, Address	28 West 36th Street, 8th Floor
Office Lease, City State Zip	New York, NY 10018
Office Lease, Term (Mos)	13
Office Lease, Monthly Payment	$ 8,900
Private Placement Offering
Private Placement, Maximum Shares | shares	50,000,000
Private Placement, Warrants	50,000,000
Private Placement, Maximum Offering ($)	$ 6,000,000
Private Placement, Warrants, Exercise Price | $ / shares	$ 0.25
Private Placement, Warrants, Life (Years)	3
Private Placement, Price Per Share | $ / shares	$ 0.125
Private Placement, Minimum Offering ($)	$ 1,000,000
Private Placement, Minimum Investment, Shaes | shares	200,000
Private Placement, Minimum Investment ($)	$ 25,000
Private Placement, SAFE Offering, Discount (Pct)	20.00%
Private Placement, Initial Closing Date	Jun. 15, 2019
Private Placement, Placement Agent	Maxim Group, LLC
Private Placement, Placement Fee (Pct)	7.00%
Private Placement, Placement Fee (Pct), Warrants	7.00%
Private Placement, Placement Fee (Pct), Warrants, Exercise Price | $ / shares	$ 0.125
Stock Issuance, Equity Funding
Stock Issuance, For Cash, Shares | shares	6,000,000
Stock Issuance, For Cash, Proceeds	$ 500,000
Stock Issuance, For Cash, Paid In Capital	$ 494,000